<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="pmc-domain-id">1692</journal-id><journal-id journal-id-type="pmc-domain">nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10096710</article-id><article-id pub-id-type="pmcid-ver">PMC10096710.1</article-id><article-id pub-id-type="pmcaid">10096710</article-id><article-id pub-id-type="pmcaiid">10096710</article-id><article-id pub-id-type="pmid">37049400</article-id><article-id pub-id-type="doi">10.3390/nu15071559</article-id><article-id pub-id-type="publisher-id">nutrients-15-01559</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Acute Administration of Ojeok-san Ameliorates Pain-like Behaviors in Pre-Clinical Models of Inflammatory Bowel Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Patton</surname><given-names initials="EA">Emma A.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cunningham</surname><given-names initials="P">Patrice</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noneman</surname><given-names initials="M">Matthew</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Helms</surname><given-names initials="HP">Henry P.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martinez-Muniz</surname><given-names initials="G">Gustavo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sumal</surname><given-names initials="AS">Aman S.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dhameja</surname><given-names initials="MK">Milan K.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Unger</surname><given-names initials="CA">Christian A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alahdami</surname><given-names initials="AK">Ahmed K.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Enos</surname><given-names initials="RT">Reilly T.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chatzistamou</surname><given-names initials="I">Ioulia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2427-165X</contrib-id><name name-style="western"><surname>Vel&#225;zquez</surname><given-names initials="KT">Kandy T.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="c1-nutrients-15-01559" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cho</surname><given-names initials="YE">Young-Eun</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-nutrients-15-01559">Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209, USA</aff><author-notes><corresp id="c1-nutrients-15-01559"><label>*</label>Correspondence: <email>kandy.velazquez@uscmed.sc.edu</email>; Tel.: +1-(803)-216-3413</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>15</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">433388</issue-id><elocation-id>1559</elocation-id><history><date date-type="received"><day>07</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>20</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-14 16:10:31.860"><day>14</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nutrients-15-01559.pdf"/><abstract><p>(1) Background: Gastrointestinal pain and fatigue are the most reported concerns of patients with inflammatory bowel disease (IBD). Commonly prescribed drugs focus on decreasing excessive inflammation. However, up to 20% of IBD patients in an &#8220;inactive&#8221; state experience abdominal pain. The medicinal herb Ojeok-san (OJS) has shown promise in the amelioration of visceral pain. However, no research on OJS has been conducted in preclinical models of IBD. The mechanism by which OJS promotes analgesia is still elusive, and it is unclear if OJS possesses addictive properties. (2) Aims: In this study, we examined the potential of OJS to promote analgesic effects and rewarding behavior. Additionally, we investigated if tumor necrosis factor alpha (TNF&#945;) from macrophages is a primary culprit of IBD-induced nociception. (3) Methods: Multiple animal models of IBD were used to determine if OJS can reduce visceral nociception. TNF&#945;-macrophage deficient mice were used to investigate the mechanism of action by which OJS reduces nociceptive behavior. Mechanical sensitivity and operant conditioning tests were used to determine the analgesic and rewarding effects of OJS. Body weight, colon length/weight, blood in stool, colonic inflammation, and complete blood count were assessed to determine disease progression. (4) Results: OJS reduced the evoked mechanical nociception in the dextran sulphate sodium model of colitis and IL-10 knockout (KO) mice and delayed aversion to colorectal distension in C57BL/6 mice. No rewarding behavior was observed in OJS-treated IL-10 KO and mdr1a KO mice. The analgesic effects of OJS are independent of macrophage TNF&#945; levels and IBD progression. (5) Conclusions: OJS ameliorated elicited mechanical and visceral nociception without producing rewarding effects. The analgesic effects of OJS are not mediated by macrophage TNF&#945;.</p></abstract><kwd-group><kwd>TNF&#945;</kwd><kwd>mechanical sensitivity</kwd><kwd>aversion</kwd><kwd>conditioning place preference</kwd><kwd>colorectal distension</kwd></kwd-group><funding-group><award-group><funding-source>Department of Pathology, Microbiology &amp; Immunology Startup Funds at University of South Carolina</funding-source></award-group><award-group><funding-source>National Institutes of Health</funding-source><award-id>K99/R00AT009206</award-id><award-id>K01-AT010348</award-id></award-group><award-group><funding-source>Sloan Scholars Mentoring Network</funding-source><award-id>Mentor-Mentee Grant</award-id><award-id>Seed Grant</award-id></award-group><award-group><funding-source>Office of the Vice President for Research</funding-source></award-group><award-group><funding-source>South Carolina Honors College</funding-source></award-group><funding-statement>This research was supported by the Department of Pathology, Microbiology &amp; Immunology Startup Funds at University of South Carolina [K.T.V.], The National Institutes of Health [K.T.V., K99/R00AT009206 and R.T.E., K01-AT010348], Sloan Scholars Mentoring Network [K.T.V., Mentor-Mentee Grant and Seed Grant], Office of the Vice President for Research [E.A.P., Magellan Scholar], and South Carolina Honors College [M.N., Science Undergraduate Research Fellowship Program].</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-nutrients-15-01559"><title>1. Introduction</title><p>An estimated 1.6 million U.S adults have been diagnosed with inflammatory bowel disease (IBD) [<xref rid="B1-nutrients-15-01559" ref-type="bibr">1</xref>,<xref rid="B2-nutrients-15-01559" ref-type="bibr">2</xref>]. Colitis is an IBD that is characterized by inflammation of the colorectum. Diarrhea, weight loss, and rectal bleeding are common side effects associated with extensive and long-lasting inflammation. A total of 70% of patients suffering from IBD will report abdominal and rectal pain [<xref rid="B3-nutrients-15-01559" ref-type="bibr">3</xref>,<xref rid="B4-nutrients-15-01559" ref-type="bibr">4</xref>,<xref rid="B5-nutrients-15-01559" ref-type="bibr">5</xref>]. This visceral pain (VP) will often dissipate as the patient recovers. However, approximately 20% of patients continue to experience this pain, even as the disease activity decreases [<xref rid="B6-nutrients-15-01559" ref-type="bibr">6</xref>]. Anti-Inflammatory treatments for IBD, such as corticosteroids, 5-aminosalicylic acid, biologics, and immunomodulators, often decrease the symptoms of the disease but have very little effect on the patient&#8217;s VP [<xref rid="B7-nutrients-15-01559" ref-type="bibr">7</xref>,<xref rid="B8-nutrients-15-01559" ref-type="bibr">8</xref>,<xref rid="B9-nutrients-15-01559" ref-type="bibr">9</xref>]. The use of common painkillers, such as narcotics and non-steroidal anti-inflammatory drugs, has been shown to aid in the management of VP, but has exhibited adverse reactions in the gastrointestinal system [<xref rid="B10-nutrients-15-01559" ref-type="bibr">10</xref>,<xref rid="B11-nutrients-15-01559" ref-type="bibr">11</xref>]. Furthermore, the use of narcotic painkillers presents a risk of inducing drug dependencies in patients [<xref rid="B12-nutrients-15-01559" ref-type="bibr">12</xref>,<xref rid="B13-nutrients-15-01559" ref-type="bibr">13</xref>]. Previous studies have found that an estimated 5% of all IBD patients may experience drug dependency [<xref rid="B12-nutrients-15-01559" ref-type="bibr">12</xref>,<xref rid="B14-nutrients-15-01559" ref-type="bibr">14</xref>]. Without a reliable and safe method to combat the VP associated with colitis, patients continue to suffer from the pain of the disease and the side effects of the treatment [<xref rid="B15-nutrients-15-01559" ref-type="bibr">15</xref>]. The utilization of novel therapies, such as complementary and integrative medicine, may elicit improvements in the treatment of VP in those with colitis.</p><p>Tumor necrosis factor alpha (TNF&#945;) is a pro-inflammatory cytokine that can be produced by myeloid cells, such as macrophages (M&#981;s) [<xref rid="B16-nutrients-15-01559" ref-type="bibr">16</xref>]. TNF&#945; has been shown to play a role in the promotion of cancer pain, and exhibits upregulated expression in the later stages of colorectal cancer [<xref rid="B17-nutrients-15-01559" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-15-01559" ref-type="bibr">18</xref>,<xref rid="B19-nutrients-15-01559" ref-type="bibr">19</xref>,<xref rid="B20-nutrients-15-01559" ref-type="bibr">20</xref>]. In patients with IBD, the increase of inflammation caused by TNF&#945; can lead to a disruption in the integrity of the mucosal barrier, which is created by the interstitial epithelial cells of the colon [<xref rid="B21-nutrients-15-01559" ref-type="bibr">21</xref>]. Without this protective layer, the colon may experience excessive damage, emanating from a decreased ability to regulate homeostasis [<xref rid="B22-nutrients-15-01559" ref-type="bibr">22</xref>]. TNF&#945; further prolongs the inflammation by activating the nuclear factor kappa B (NF&#954;&#946;)-dependent pathways, which increase the expression of many cytokines and enzymes, and by upregulating other pro-inflammatory molecules, such as interleukin-1&#946; and interleukin-6 [<xref rid="B23-nutrients-15-01559" ref-type="bibr">23</xref>]. Therefore, the association between M&#981;s and TNF&#945; production could be the key to understanding the pathogenesis of VP.</p><p>Ojeok-san (OJS), a medicinal herbal formula, is commonly used in Traditional Korean Medicine, Traditional Chinese Medicine (Wu-ji-san) and Kampo Japanese Medicine (Goshaku-san) as a way to combat pain, gastrointestinal problems, depression, and the common cold, among others [<xref rid="B24-nutrients-15-01559" ref-type="bibr">24</xref>,<xref rid="B25-nutrients-15-01559" ref-type="bibr">25</xref>]. Previous experimental studies that have utilized this remedy have shown to have anti-pyretic, anti-inflammatory, anti-metastatic, and analgesic properties [<xref rid="B24-nutrients-15-01559" ref-type="bibr">24</xref>,<xref rid="B26-nutrients-15-01559" ref-type="bibr">26</xref>,<xref rid="B27-nutrients-15-01559" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-15-01559" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-15-01559" ref-type="bibr">29</xref>,<xref rid="B30-nutrients-15-01559" ref-type="bibr">30</xref>,<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>,<xref rid="B32-nutrients-15-01559" ref-type="bibr">32</xref>]. These effects were observed with minimal to no discernable toxicity in the organs and cells of patients [<xref rid="B27-nutrients-15-01559" ref-type="bibr">27</xref>]. While the use of OJS may seem like the obvious choice for the treatment of VP in IBD, the mechanism by which OJS diminishes VP in patients is unknown. When used for in vitro studies, OJS has been shown to increase apoptosis and reduce inflammation through the activation of caspase-3 and a decrease in the expression of cytokines and macrophage-derived chemokines, respectively [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>,<xref rid="B33-nutrients-15-01559" ref-type="bibr">33</xref>,<xref rid="B34-nutrients-15-01559" ref-type="bibr">34</xref>,<xref rid="B35-nutrients-15-01559" ref-type="bibr">35</xref>,<xref rid="B36-nutrients-15-01559" ref-type="bibr">36</xref>]. In fact, we have previously shown that OJS can reduce TNF&#945; gene expression from macrophages in a dose-dependent matter [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>]. Therefore, it is possible that OJS could ameliorate colitis and/or colitis symptoms, such as visceral hypersensitivity, by inhibiting TNF&#945; release from macrophages.</p><p>Due to a number of studies that have shown a link between increased TNF&#945; levels and pathogenesis of IBD [<xref rid="B37-nutrients-15-01559" ref-type="bibr">37</xref>,<xref rid="B38-nutrients-15-01559" ref-type="bibr">38</xref>,<xref rid="B39-nutrients-15-01559" ref-type="bibr">39</xref>], as well as the therapeutic potential of anti-TNF&#945; therapy and soluble TNF&#945; receptors [<xref rid="B40-nutrients-15-01559" ref-type="bibr">40</xref>], we sought to investigate the role of macrophage-secreted TNF&#945; and OJS administration in colitis.</p></sec><sec id="sec2-nutrients-15-01559"><title>2. Material and Methods</title><sec id="sec2dot1-nutrients-15-01559"><title>2.1. Experimental Animals</title><p>Experiments conducted in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of South Carolina. The mice were held in ventilated cages and cared for in accordance with institutional guidelines (12 h:12 h light-dark cycle, 50% humidity, 22 &#176;C temperature, low noise). All mice were a fed purified Ain76A diet ad libitum (Bio-Serv, Frenchtown, NJ, USA). Dextran sulfate sodium (DSS) was used to induce colitis in mutant mice that had TNF&#945; deleted from their myeloid cells (TNF&#945; <sup>flox/flox LysMcre</sup>), as well as in littermate control WT mice. Ojeok-san was administered orally to investigate its role in mitigating colitis progression, histopathology, and visceral hyperalgesia. We used conditioning paradigms to determine as to whether OJS has rewarding effects in two models of spontaneous colitis (mdr1a constitutive knockout (multi-drug resistance genes, Abcb1a) and interleukin-10-deficient mice). Subsequently, we subjected C57BL6 (wild-type) mice to an aversive-conditioning test using colorectal balloon distension, in order to determine the non-reflexive analgesic properties of OJS.</p><sec id="sec2dot1dot1-nutrients-15-01559"><title>2.1.1. Experiment #1</title><p>Female and male TNF&#945; <sup>flox/flox LysMcre</sup> and littermate control TNF&#945; <sup>flox/flox</sup> mice were used in this experiment [<xref rid="B41-nutrients-15-01559" ref-type="bibr">41</xref>,<xref rid="B42-nutrients-15-01559" ref-type="bibr">42</xref>]. TNF&#945; <sup>flox/flox</sup> mice have an increased production of TNF&#945; (normal response), while TNF&#945; <sup>flox/flox LysMcre</sup> mice exhibit a significantly blunted TNF&#945; response to lipopolysaccharide, due to the decreased production of TNF&#945; from myeloid cells, such as macrophages, monocytes, and granulocytes [<xref rid="B41-nutrients-15-01559" ref-type="bibr">41</xref>,<xref rid="B42-nutrients-15-01559" ref-type="bibr">42</xref>,<xref rid="B43-nutrients-15-01559" ref-type="bibr">43</xref>]. Mice (male and female, approximately 20 weeks old) were allocated into eight groups following stratified random sampling in terms of genotype, litter, sex, and body weight: TNF&#945; flox/flox Control Vehicle, TNF&#945; flox/flox DSS Vehicle, TNF&#945; flox/flox Control Ojeok-san, TNF&#945; flox/flox DSS Ojeok-san, TNF&#945; flox/flox LysMcre Control Vehicle, TNF&#945; flox/flox LysMcre DSS Vehicle, TNF&#945; flox/flox LysMcre Control Ojeok-san, and TNF&#945; flox/flox LysMcre DSS Ojeok-san. The experiments were conducted in four blocks. Water intake and disease activity index were assessed every day. Mechanical sensitivity to von Frey filaments was assessed on day 5. On day 7, mice were euthanized with an overdose of isoflurane, and their blood, plasma, and the colorectum was collected for further analysis.</p></sec><sec id="sec2dot1dot2-nutrients-15-01559"><title>2.1.2. Experiment #2</title><p>Female and male mdr1a constitutive knockout mice were obtained from Taconic (Germantown, NY, USA). Mdr1a (multidrug resistance genes Abcb1a) KO mice have an intact immune system and develop spontaneous colitis, which is similar to human IBD, between 8 and 36 weeks of age [<xref rid="B44-nutrients-15-01559" ref-type="bibr">44</xref>,<xref rid="B45-nutrients-15-01559" ref-type="bibr">45</xref>]. By 20 weeks of age, all mdr1a KO mice developed colitis, which was determined by the presence of loose bloody stools (ColoScreen Tape, Helena Laboratories, Beumont, TX, USA). At 28 weeks of age, mdr1a KO mice were exposed to an automated Spatial Place Preference Box (Harvard Apparatus, Holliston, MA, USA), in order to determine the analgesic drug&#8217;s efficacy against spontaneous colitis [<xref rid="B46-nutrients-15-01559" ref-type="bibr">46</xref>]. Colon weight and length were measured, and blood was collected for cell blood count.</p></sec><sec id="sec2dot1dot3-nutrients-15-01559"><title>2.1.3. Experiment #3</title><p>Interleukin-10 mutant (IL-10 KO) mice were originally obtained from Jackson Lab (B6.129P2-<sup>Il10tm1Cgn/J</sup>, Strain no. 002251) and bred at the University of South Carolina. This mouse genotype was selected due to the spontaneous development of chronic enterocolitis [<xref rid="B47-nutrients-15-01559" ref-type="bibr">47</xref>]. Regarding baseline mechanical sensitivity, young-adult (up to 12 weeks old) IL-10-deficient mice do not differ from WT mice [<xref rid="B48-nutrients-15-01559" ref-type="bibr">48</xref>,<xref rid="B49-nutrients-15-01559" ref-type="bibr">49</xref>,<xref rid="B50-nutrients-15-01559" ref-type="bibr">50</xref>,<xref rid="B51-nutrients-15-01559" ref-type="bibr">51</xref>]. Mechanical sensitivity was assessed at 7 months of age in male and female IL-10 KO mice. The mechanical threshold was defined as the force in grams, by which an animal reacts to 80% of the stimuli. Behavioral and metabolic phenotyping was conducted at approximately 8 months of age. The conditioned place preference test was performed at approximately 12 months of age. Body weight, colon weight, colon length, and blood were collected following euthanasia.</p></sec><sec id="sec2dot1dot4-nutrients-15-01559"><title>2.1.4. Experiment #4</title><p>C56BL/6 mice were obtained from Jackson lab and bred at the University of South Carolina. Male and female C57BL/6 mice were used, due to their visceral sensitivity response to colorectal distension [<xref rid="B52-nutrients-15-01559" ref-type="bibr">52</xref>]. A conditioned place aversion test was performed at 24&#8211;25 months of age. Body weight was measured, and blood collected for complete blood count.</p></sec></sec><sec id="sec2dot2-nutrients-15-01559"><title>2.2. Dextran Sulphate Sodium (DSS) Colitis Development</title><p>For the chemical model of colitis, dextran sulfate sodium (DSS), was used due to the rapid development of colitis and visceral hypersensitivity [<xref rid="B53-nutrients-15-01559" ref-type="bibr">53</xref>]. DSS (2%) was obtained from TdB Labs (Uppala, Sweden), and supplied to the mice in their drinking water for a 5-day period.</p></sec><sec id="sec2dot3-nutrients-15-01559"><title>2.3. Ojeok-san Administration</title><p>Ojeok-san (2 g/kg body weight) was obtained from Dr. Hyeun-Kyoo Shin (Director of the Herbal Medicine Formulation Research Group at the Korean Institute of Oriental Medicine). This herbal formula contains the following herbs: Atractylodis Rhizoma (<italic toggle="yes">Atracylodes lancea D.C</italic>., 7.5 g), Ephedrae Herba (<italic toggle="yes">Ephedra sinica</italic> Stapf, 3.75), Citri Unshius Pericarpium (<italic toggle="yes">Citrus unshiu</italic> Markovich, 3.75), Magnoliae Cortex (<italic toggle="yes">Magnolia officinalis</italic> Rehd. Et Wils., 3.0), Platycodonis Radix (<italic toggle="yes">Platycodon grandiflorum</italic> A. DC., 3.0) Aurantii Fructus Immaturus (<italic toggle="yes">Citrus</italic> unshiu Markovich, 3.0), Angelicae Gigantis Radix (<italic toggle="yes">Angelica gigas</italic> Nakai, 3.0), Zingiberis Rhizoma (<italic toggle="yes">Zingiber officinale</italic> Rosc., 3.0), Paeoniae Radix (<italic toggle="yes">Paeonia lactiflora</italic> Pall., 3.0), Poria Sclerotium (<italic toggle="yes">Poria cocos</italic> Wolf, 3.0), Angelicae Dahuricae Radix (<italic toggle="yes">Angelica dahurica</italic> Benth. Et Hook. F., 3.0), Cnidii Rhizoma (<italic toggle="yes">Cnidium officinale</italic> Makino, 2.63), Pinelliae Tuber (<italic toggle="yes">Pinellia ternata</italic> Breit., 2.63), Cinnamomi Cortex (<italic toggle="yes">Cinnamomum cassia</italic> Presi, 2.63), Glycyrrhizae Radix et Rhizoma (<italic toggle="yes">Glycyrrhiza uralensis</italic> Fisch. 2.25), Zingiberis Rhizoma Recens (<italic toggle="yes">Zingiber officinale</italic> Rosc., 3.75), and Allii Fistulosi Bulbus (<italic toggle="yes">Allium fistulosum</italic> L., 3.75). Mice were lightly anesthetized (mix of isoflurane and oxygen), then gavaged (22 g &#215; 55 mm, Instech Laboratories, Plymouth Meeting, PA, USA) with 2 g/kg of Ojeok-san, either dissolved in water or vehicle (water). Mice were allowed to recover from the anesthesia for 10 min prior to any behavioral test [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>].</p></sec><sec id="sec2dot4-nutrients-15-01559"><title>2.4. Disease Activity Index, Histology, and Complete Blood Count</title><p>The disease activity index was calculated based on the sum of score-related symptoms (body weight loss (&gt;5%WL = 0; 6&#8211;10%WL = 1; 11&#8211;15%WL = 2; 16&#8211;20% = 3, 21&#8211;25% = 4), stool consistency (pellet = 0; pasty = 2; liquid = 4), and blood in the stool (negative = 0, positive = 2, gross bleeding = 4)) [<xref rid="B20-nutrients-15-01559" ref-type="bibr">20</xref>]. The distal portion of the colorectum was dissected, weighed, measured, fixed in 4% paraformaldehyde, and stained with H&amp;E and Alcian blue. H&amp;E slides were evaluated (blinded to treatment groups) and scored according to the severity and extent of inflammatory cell infiltrate (1 = mild; 2 = moderate; 3 = marked), intestinal architecture, and epithelial changes (1 = focal erosions; 2 = erosions; 3 = extended erosions) by a certified pathologist (I.C.) [<xref rid="B54-nutrients-15-01559" ref-type="bibr">54</xref>]. Goblet cells were counted per six crypts and villus length was measured by Alcian blue-stained slides in a blinded fashion (P.C.). Blood was collected from the inferior vena cava using a heparinized needle and placed in a VetScan Hm5 (Abaxis, Union City, CA, USA) for hematology analysis. The blood was then centrifuged to separate the plasma, which was then stored at &#8722;80 &#176;C for further testing.</p></sec><sec id="sec2dot5-nutrients-15-01559"><title>2.5. Real-Time PCR</title><p>The proximal portion of the colon was used to determine the expression level of genes associated with pain (calcitonin receptor, calcr; mu opioid receptor, oprm; kappa opioid receptor, oprk) and colitis (interleukin-6, IL-6; nucleotide-binding oligomerization domain-containing 2, NOD2; TNF&#945;; interleukin-4 (IL-4)) using qRT-PCR. Briefly, colonic RNA isolation was performed using trizol, chloroform, and isopropanol, and samples were purified with lithium chloride [<xref rid="B55-nutrients-15-01559" ref-type="bibr">55</xref>]. The RNA concentration and purity were assessed using a NanoDrop (ThermoFisher, Waltham, MA, USA). An iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) was used to convert RNA into cDNA. Bio-rad probes were used to determine the expression of pain and colitis markers, using TATA box binding protein (TBP), ubiquitin C (UBC), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping genes.</p></sec><sec id="sec2dot6-nutrients-15-01559"><title>2.6. Behavioral Tests</title><p>The mechanical sensitivity to von Frey filaments (0.008, 0.02, 0.04, 0.07, 0.16, 0.40, 0.6, 1.0, 1.4, 2, 4, 6 g) was assessed on day 5 (10 min after oral administration of Ojeok-san or water), after a 3 day habituation period [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>]. The mechanical threshold was defined as the force in grams at which any von Frey filament elicited 5 nociceptive responses (jumping, sharp retraction from the abdomen, and immediate licking or scratching of the lower abdomen) out of 5 stimuli. All mechanical sensitivity tests were performed between 7&#8211;9 am (beginning of light cycle) by the same investigator, who was blinded to the treatment groups. Additionally, the experimenter analyzing the data was blinded to group assignments.</p><p>The conditioned place preference (CPP) test was conducted using an automated Spatial Place Preference Box (Harvard Apparatus, Holliston, MA, USA), in order to examine the affective component of pain in colitis. This paradigm was conducted over a total of 4&#8211;5 weeks. Prior to the beginning of the first trial, an initial place preference of each mouse was obtained by allowing each mouse free range within the three-compartment Spatial Place Preference Box for 15 min. Chamber preference (baseline) was assessed by an automated weight transducer technology, which detected the animal&#8216;s position. For experiment #2, two conditioning trials (45 min each/day for two days) were performed in the morning (mice conditioned to the preferred side, with oral administration of water) and in the afternoon (mice conditioned to non-preferred side, with oral administration of 2 g/kg body weight of Ojeok-san or water). During the test days, (drug-free) mice were allowed to move freely through the three-compartment chamber (15 min). Four or five drug free preference tests were conducted after 4 days of conditioning trials. Preference testing tests were conducted between 7:30 a.m. and 9:30 a.m. Conditioning trials were performed between 7 a.m. and 11 a.m. for morning conditioning and between 11 a.m. and 3 p.m. for afternoon conditioning. Four consecutive conditioning trials and preference tests were conducted. The percentage of time spent in the non-preferred (Ojeok-san conditioning) compartment was calculated as follows: time (s) spent in the non-preferred compartment, divided by the time (s) spent in the three compartments (preferred, non-preferred, and corridor), multiplied by 100. The total number of entries into the compartments was also calculated, in order to assess general locomotor activity. In experiment #3, we modified the conditioned place preference protocol due to the number of animals and time constraints. After assessing chamber preference, animals were conditioned (oral gavage of water and/or Ojeok-san) for four days to the non-preferred chamber for 45 min. On the 5th day (drug-free preference testing) of each conditioned trial, mice were allowed free range to the Special Place Preference Box and the time spent in each chamber was monitored.</p><p>Behavioral and metabolic phenotyping were assessed for nine days using the Promethion System (Sable Systems International, Las Vegas, NV, USA). Prior to placing the mice in the automated Promethion System, a single dose of oral Ojeok-san (2 g/kg of body weight) and/or vehicle (water) was administered to IL-10 KO mice. Ambulatory locomotion time, still time, and sleep time were obtained, in order to determine the effects of OJS on spontaneous behaviors during the light and night cycles.</p><p>A conditioned place-aversion experiment (automated Spatial Place Preference Box from Harvard Apparatus, Holliston, MA, USA) was performed to examine if OJS can hinder the aversive features of colorectal distension (Barostat, Distender Series II, G&amp;J Electronics) [<xref rid="B56-nutrients-15-01559" ref-type="bibr">56</xref>]. During baseline measurements, mice were allowed to explore the three-compartment Spatial Place Preference Box for 15 min. Four conditioning trials of approximately 60 min/day were performed prior to each test day (Tests 1&#8211;5). The repeated phasic distension protocol consisted of twelve 55 mmHg pressure stimuli, with a 20 s duration each and with 5 min rest (non-inflated balloon) intervals. Mice were anesthetized (isoflurane) prior to balloon insertion and the administration of Ojeok-san (2 g/kg of body weight) and/or water via oral gavage. Mice were allowed to recover from the anesthesia for 10 min prior to the start of conditioning with an aversive stimulus (colorectal balloon distension). Drug-free/CRD-free testing was conducted for 15 min, during which mice were allowed to move freely through the three-compartment chamber. The percentage of time spent in the preferred chamber was graphed. Preconditioning (baseline), conditioning trials, and drug-free tests were conducted between 7 a.m. and 11 a.m. The percentage of time spent in the preferred (aversion conditioning) compartment was calculated as follows: time (s) spent in the preferred compartment divided by the time (s) spent in the three compartments (preferred, non-preferred, and corridor), and multiplied by 100.</p></sec><sec id="sec2dot7-nutrients-15-01559"><title>2.7. Data Analysis</title><p>Data were analyzed using GraphPad software, Prism 8.0. A three-way ANOVA (disease &#215; genotype &#215; treatment) with a Fisher&#8217;s LSD post hoc analysis was used to assess body weight, colon length, colon weight, histopathology, villus length, goblet cell count, gene expression, immune cell count, and mechanical threshold outcomes in Experiment #1. Water intake and the disease activity index in Experiment #1 were analyzed using a mixed-effects model followed by Fisher&#8217;s LSD. For Experiments #2, 3, and 4, colon weight, colon length, and complete blood count were analyzed using unpaired Student&#8217;s <italic toggle="yes">t</italic>-tests. The conditioned place-preference and conditioned place-aversion tests were analyzed using a two-way RM ANOVA, followed by Fisher&#8217;s LSD. Statistical data that did not pass the equal variance test (Barlett&#8217;s Test) were logarithmically transformed and further analyzed. The level of significance was set at <italic toggle="yes">p</italic> &lt; 0.05 and the data are presented as means standard error.</p></sec></sec><sec sec-type="results" id="sec3-nutrients-15-01559"><title>3. Results</title><sec id="sec3dot1-nutrients-15-01559"><title>3.1. Macrophage TNF&#945; Deletion and Ojeok-san Administration Do Not Impact Disease Progression in a Chemical Model of Acute Colitis</title><p>To determine the impact that OJS administration and macrophage TNF&#945; deletion (TNF&#945;fl/fl-LysMcre) have on disease progression, we assessed body weight, disease activity index, colon length and weight, histopathological score, villus length, and goblet cell number (<xref rid="nutrients-15-01559-f001" ref-type="fig">Figure 1</xref>A). As expected, mice that received DSS exhibited a significant decrease in body weight when compared to TNF&#945; fl/fl Control-Vehicle (WT) (<xref rid="nutrients-15-01559-f001" ref-type="fig">Figure 1</xref>B, <italic toggle="yes">p</italic> &lt; 0.05). There was a main effect of the TNF&#945;fl/fl-LysMcre genotype, regarding a decrease in body weight. Regarding OJS administration, no main effect of treatment was observed. No changes in water intake were observed between treatment groups (<xref rid="nutrients-15-01559-f001" ref-type="fig">Figure 1</xref>C,D). No changes in the disease activity index were observed in mice that did not receive DSS (<xref rid="nutrients-15-01559-f001" ref-type="fig">Figure 1</xref>E). A main difference in time was found for the disease activity index for all treatment groups that received DSS (<xref rid="nutrients-15-01559-f001" ref-type="fig">Figure 1</xref>F, <italic toggle="yes">p</italic> &lt; 0.05), indicative of a typical colitis progression (body weight loss, diarrhea, and blood in stool).</p><p><xref rid="nutrients-15-01559-f002" ref-type="fig">Figure 2</xref>A,B are representative colon tissue H&amp;E images from control and colitis mice, respectively. There was a main effect of the disease (colitis), in terms of decreasing colon length, increasing colon weight, and exacerbating inflammation in mice with colitis (<xref rid="nutrients-15-01559-f002" ref-type="fig">Figure 2</xref>C,E, <italic toggle="yes">p</italic> &lt; 0.0001). TNF&#945;fl/fl-LysMcre Control-OJS mice displayed a shorter colon length relative to TNF&#945;fl/fl Control-OJS mice (<italic toggle="yes">p</italic> = 0.0382). An interaction between genotype and disease was found to decrease the inflammatory score in TNF&#945;fl/fl-LysMcre Control-Vehicle mice when compared to TNF&#945;fl/fl Control-Vehicle mice (<italic toggle="yes">p</italic> = 0.004).</p><p>Goblet cells in the colon tissue were visualized using an Alcian blue stain (<xref rid="nutrients-15-01559-f003" ref-type="fig">Figure 3</xref>A,B). The average number of goblet cells was determined per six crypts, and villus length was measured. DSS treatment was found to decrease villus length and goblet cell number in colitis mice (<xref rid="nutrients-15-01559-f003" ref-type="fig">Figure 3</xref>C,D, <italic toggle="yes">p</italic> &lt; 0.001). An interaction between disease and genotype was found to result in an increased villus length in TNF&#945;fl/fl-LysMcre Control- Vehicle and OJS-treated mice, as well as TNF&#945;fl/fl Control-OJS mice, relative to TNF&#945;fl/fl Control-Vehicle mice, suggesting that TNF&#945; deletion from macrophages has an impact on villus length (<italic toggle="yes">p</italic> = 0.0443). An interaction between disease and treatment was found to decrease goblet cells in Control-OJS-treated TNF&#945;fl/fl-LysMcre mice relative to Control-Vehicle-treated TNF&#945;fl/fl-LysMcre mice (<italic toggle="yes">p</italic> = 0.0133). However, no difference was detected in the number of goblet cells between TNF&#945;fl/fl Control-OJS and TNF&#945;fl/fl DSS-OJS mice. DSS treatment was found to increase the gene expression of inflammatory genes, interleukin-6 (IL-6) and nucleotide-binding oligomerization domain-containing 2 (NOD2) (<xref rid="nutrients-15-01559-f003" ref-type="fig">Figure 3</xref>E,F, <italic toggle="yes">p</italic> = 0.022), but no significant changes were observed in terms of TNF&#945; and interleukin-4 (IL-4) levels in the colon (<xref rid="app1-nutrients-15-01559" ref-type="app">Supplementary Figure S1</xref>). An interaction between disease and treatment was found to increase IL-6 expression in TNF&#945;fl/fl-LysMcre DSS-OJS mice relative to all groups (<italic toggle="yes">p</italic> = 0.0232).</p></sec><sec id="sec3dot2-nutrients-15-01559"><title>3.2. Macrophage Deletion of TNF&#945; Does Not Impact the Blood Profile but Ojeok-san Administration Diminishes Lymphocyte Levels in Mice with Colitis</title><p>To examine the impact that OJS administration and macrophage TNF&#945; deletion has on the blood profile, a complete blood count was performed (<xref rid="nutrients-15-01559-f004" ref-type="fig">Figure 4</xref>A&#8211;F). A consequence of the disease was an increase in monocytes (MON, <italic toggle="yes">p</italic> = 0.0087), neutrophils (NEU, <italic toggle="yes">p</italic> = 0.0012), and platelets (PLT, <italic toggle="yes">p</italic> = 0.0054), and a decrease in red blood cells (RBC, <italic toggle="yes">p</italic> = 0.0031) and hemoglobin (HBG, <italic toggle="yes">p</italic> = 0.0003). A main effect of treatment was a decrease in the number of lymphocytes (<italic toggle="yes">p</italic> = 0.0227) in the blood of TNF&#945;fl/fl DSS-OJS mice relative to TNF&#945;fl/fl Control-vehicle, TNF&#945;fl/fl DSS-Vehicle, and TNF&#945;fl/fl-LysMcre Control-Vehicle mice. Furthermore, lymphocyte levels were decreased (LYM, <italic toggle="yes">p</italic> = 0.0227) in TNF&#945;fl/fl-LysMcre DSS-Vehicle mice when compared to TNF&#945;fl/fl Control-Vehicle mice.</p></sec><sec id="sec3dot3-nutrients-15-01559"><title>3.3. Deletion of Macrophage TNF&#945; Does Not Impact Mechanical Sensitivity but Ojeok-san Administration Improves Mechanical Hyperalgesia in Mice with Colitis</title><p>To assess the mechanical sensitivity and gauge the response of the mice to nociception, mechanical threshold to von Frey filaments was measured. Effects of both disease and treatment were detected in the mice during the nociceptive behavior sensitivity test (<xref rid="nutrients-15-01559-f005" ref-type="fig">Figure 5</xref>A, <italic toggle="yes">p</italic> &lt; 0.05). Mice with colitis exhibited increased mechanical sensitivity (lower mechanical threshold) and DSS mice treated with OJS showed decreased mechanical hyperalgesia (increased mechanical threshold). We next addressed whether OJS is capable of controlling pain signaling at the level of the nociceptors. Both the disease and treatment were found to decrease calcitonin receptor (calcr) gene expression (<xref rid="nutrients-15-01559-f005" ref-type="fig">Figure 5</xref>B, <italic toggle="yes">p</italic> &lt; 0.05). Interestingly, an interaction between the treatment and genotype (<italic toggle="yes">p</italic> = 0.0232) was found to increase calcr gene expression in the colon tissue of TNF&#945;fl/fl-LysMcre Control-Vehicle mice. Gene expression of the &#956;-opioid receptor (oprm) and &#954;-opioid receptor (oprk) was also examined (<xref rid="nutrients-15-01559-f005" ref-type="fig">Figure 5</xref>C,D). OJS treatment was found to decrease the gene expression of oprm and oprk (<italic toggle="yes">p</italic> &lt; 0.05).</p></sec><sec id="sec3dot4-nutrients-15-01559"><title>3.4. Four Weeks of Ojeok-san Administration Does Not Impact Disease Progression nor Show Rewarding Properties in the mdr1a KO Mouse Model of Spontaneous Colitis</title><p>To evaluate whether OJS has the potential to become addictive, we utilized a spatial conditioned place-preference paradigm to assess OJS&#8217;s rewarding properties. For this test, we first determined initial preference for one compartment versus the other, then OJS administration was paired with the non-preferred compartment (<xref rid="nutrients-15-01559-f006" ref-type="fig">Figure 6</xref>A). Rewarding properties are associated with changes in compartment preference. Regarding disease progression, a four-week administration of OJS did not change body weight, colon weight, or colon length in mrd1a-KO mice (<xref rid="nutrients-15-01559-f006" ref-type="fig">Figure 6</xref>B,C). No difference was detected in the percentage of time spent in the non-preferred compartment among mrd1a-KO vehicle and mrd1a-KO OJS treated mice (<xref rid="nutrients-15-01559-f006" ref-type="fig">Figure 6</xref>E). To examine if a longer OJS exposure has an impact on the blood profile, we performed a complete blood count. An increase in WBC and LYM was observed in mrd1a KO OJS-treated mice when compared to mrd1a KO vehicle mice. No differences were detected between groups with respect to MON, NEU, RBC, HGB, and PLT counts.</p></sec><sec id="sec3dot5-nutrients-15-01559"><title>3.5. Five Weeks of Ojeok-san Supplementation Does Not Impact Disease Progression but Improves Mechanical Hyperalgesia without Promoting Rewarding Behavior in an IL-10 KO Mouse Model of Spontaneous Colitis</title><p>To confirm the impact of OJS on colitis, analgesia, and rewarding behavior, we utilized the IL-10 KO mouse model of spontaneous colitis (<xref rid="nutrients-15-01559-f007" ref-type="fig">Figure 7</xref>A). No differences were observed in body weight, colon weight, or colon length between the IL-10 KO vehicle and IL-10 KO OJS mice (<xref rid="nutrients-15-01559-f007" ref-type="fig">Figure 7</xref>B&#8211;D). IL-10 KO OJS-treated mice showed an elevated mechanical threshold when compared to IL-10 KO vehicle mice (<xref rid="nutrients-15-01559-f007" ref-type="fig">Figure 7</xref>E). Regarding the addictive potential of the analgesic, there was no reward-seeking behavior observed with OJS treatment in IL-10 KO mice (<xref rid="nutrients-15-01559-f007" ref-type="fig">Figure 7</xref>F). No differences were detected between IL-10 KO vehicle and IL-10 KO OJS mice with respect to WBC, LYM, MON, NEU, RBC, HGB, and PLT.</p><p>We have previously reported that OJS exhibits sedative properties in mice with colorectal cancer [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>]. However, we do not know for how long this effect can last. Therefore, we orally administered OJS (as a one-time gavage on day 0) or water (vehicle) into IL-10 KO mice to examine locomotive, still, and sleeping behaviors. As expected in nocturnal animals, an increase in locomotive activity during the night and sleep activity during the day was found over time (<xref rid="nutrients-15-01559-f008" ref-type="fig">Figure 8</xref>A,B). However, no differences were detected in locomotion and sleep time between IL-10 KO vehicle and IL-10 KO OJS mice after a single administration of OJS.</p></sec><sec id="sec3dot6-nutrients-15-01559"><title>3.6. Ojeok-san Reduces Aversive Behavior Produced by the Colorectal Balloon Distension in C57BL6 Mice</title><p>Colorectal distension is the gold standard method for evaluating colon sensitivity in animals and humans [<xref rid="B57-nutrients-15-01559" ref-type="bibr">57</xref>,<xref rid="B58-nutrients-15-01559" ref-type="bibr">58</xref>,<xref rid="B59-nutrients-15-01559" ref-type="bibr">59</xref>]. A positive correlation between pressure and visceromotor response (abdominal musculature contraction) has been associated with increased pain perception in humans [<xref rid="B56-nutrients-15-01559" ref-type="bibr">56</xref>,<xref rid="B57-nutrients-15-01559" ref-type="bibr">57</xref>,<xref rid="B59-nutrients-15-01559" ref-type="bibr">59</xref>,<xref rid="B60-nutrients-15-01559" ref-type="bibr">60</xref>]. We have previously shown that OJS reduces visceral nociception in a pre-clinical model of colorectal cancer [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>]. However, non-reflexive (operant) measurements have not been used to determine the analgesic properties of OJS. We tested OJS using a conditioned place-aversion paradigm, since colorectal distension has been shown to produce aversive behavior when using a passive avoidance behavioral paradigm [<xref rid="B56-nutrients-15-01559" ref-type="bibr">56</xref>]. Colorectal distension at a pressure of 55 mmHg elicited avoidance behavior (i.e., mice spend less time in the preferred compartment during the test day) in three out of five tests (Tests 3, 4 and 5) in C57BL6 mice that were administered water (<xref rid="nutrients-15-01559-f009" ref-type="fig">Figure 9</xref>A,B, <italic toggle="yes">p</italic> &lt; 0.05). However, mice that received OJS instead of vehicle (water) during conditioning training only showed avoidance behavior in one of the five tests (Test 4) (<italic toggle="yes">p</italic> &lt; 0.05). No differences were detected in terms of body weight, WBC, MON, or PLT between C57BL6 Vehicle and C57BL6 OJS mice (<xref rid="nutrients-15-01559-f009" ref-type="fig">Figure 9</xref>C&#8211;D,F,J). A five week administration of OJS in C57BL6 mice increased LYM, NEU, HGB, and RBC levels in the blood (<xref rid="nutrients-15-01559-f009" ref-type="fig">Figure 9</xref>E,G&#8211;I).</p></sec></sec><sec sec-type="discussion" id="sec4-nutrients-15-01559"><title>4. Discussion</title><p>Gastrointestinal pain and fatigue are the most reported concerns of patients with IBD [<xref rid="B5-nutrients-15-01559" ref-type="bibr">5</xref>,<xref rid="B61-nutrients-15-01559" ref-type="bibr">61</xref>]. Commonly prescribed drugs for IBD focus on decreasing excess inflammation without effectively managing patients&#8217; pain [<xref rid="B7-nutrients-15-01559" ref-type="bibr">7</xref>,<xref rid="B8-nutrients-15-01559" ref-type="bibr">8</xref>,<xref rid="B9-nutrients-15-01559" ref-type="bibr">9</xref>]. However, approximately 20 percent of the IBD patients in an &#8220;inactive/remission&#8221; state experience abdominal pain [<xref rid="B6-nutrients-15-01559" ref-type="bibr">6</xref>,<xref rid="B62-nutrients-15-01559" ref-type="bibr">62</xref>]. Acute and/or chronic visceral pain in patients with IBD continues to be undertreated, and the prescription of narcotics after hospitalization continues, despite opioid use being associated with increased inpatient stays, infection, and death [<xref rid="B15-nutrients-15-01559" ref-type="bibr">15</xref>,<xref rid="B63-nutrients-15-01559" ref-type="bibr">63</xref>,<xref rid="B64-nutrients-15-01559" ref-type="bibr">64</xref>]. Therefore, alternative pain relievers should be explored, given that patients continue to feel the negative effects of the disease and the current treatments. Since we have previously reported that OJS ameliorates visceral and somatic nociception [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>], and preclinical models of IBD have already been established to promote visceral nociception in rodents [<xref rid="B65-nutrients-15-01559" ref-type="bibr">65</xref>,<xref rid="B66-nutrients-15-01559" ref-type="bibr">66</xref>,<xref rid="B67-nutrients-15-01559" ref-type="bibr">67</xref>], we proposed to investigate if OJS can serve as a non-addictive alternative treatment to reduce IBD-associated nociception. We found that OJS reduces mechanical and visceral IBD-associated nociception, without causing rewarding effects. Although TNF&#945; has been identified to be an important mediator of IBD and pain development [<xref rid="B68-nutrients-15-01559" ref-type="bibr">68</xref>,<xref rid="B69-nutrients-15-01559" ref-type="bibr">69</xref>,<xref rid="B70-nutrients-15-01559" ref-type="bibr">70</xref>], mice with macrophage-derived TNF&#945; deletion did not exhibit any decreased disease severity, including that of nociceptive behavior.</p><p>Ojeok-san has been shown to decrease macrophage-mediated inflammatory processes and reduce the production of TNF&#945; [<xref rid="B33-nutrients-15-01559" ref-type="bibr">33</xref>,<xref rid="B34-nutrients-15-01559" ref-type="bibr">34</xref>]. Its anti-pyretic, anti-inflammatory, anti-metastatic, and analgesic properties make OJS a good candidate for the future treatment of IBD-associated pain [<xref rid="B24-nutrients-15-01559" ref-type="bibr">24</xref>,<xref rid="B26-nutrients-15-01559" ref-type="bibr">26</xref>,<xref rid="B27-nutrients-15-01559" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-15-01559" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-15-01559" ref-type="bibr">29</xref>,<xref rid="B30-nutrients-15-01559" ref-type="bibr">30</xref>]. The data gathered in this study show that OJS is able to decrease mechanical hyperalgesia in a chemically induced and a genetic model of a spontaneous colitis. Additionally, OJS reduced visceral, non-reflexive nociception using a conditioned place-aversion paradigm. Nociceptive behaviors have been previously observed to occur at the peak of colitis in both DSS-treated and IL-10 KO mice [<xref rid="B67-nutrients-15-01559" ref-type="bibr">67</xref>,<xref rid="B71-nutrients-15-01559" ref-type="bibr">71</xref>]. However, nociception sensitivity is not present at late and early time points in these models [<xref rid="B48-nutrients-15-01559" ref-type="bibr">48</xref>,<xref rid="B49-nutrients-15-01559" ref-type="bibr">49</xref>,<xref rid="B50-nutrients-15-01559" ref-type="bibr">50</xref>,<xref rid="B51-nutrients-15-01559" ref-type="bibr">51</xref>,<xref rid="B72-nutrients-15-01559" ref-type="bibr">72</xref>]. Some possible explanations might be due to the endogenous production of opioids by T cells in IL10-decificent mice [<xref rid="B73-nutrients-15-01559" ref-type="bibr">73</xref>] and the lack of colitis in young IL-10 KO mice. Previously, we have shown that OJS can reduce both somatic, referred hyperalgesia, as well as visceral sensitivity to a colorectal distension of 40&#8211;80 mmHg [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>]. The analgesic effects of OJS appeared to be indirect, as OJS was not able to reduce dorsal root ganglia firing in vitro [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>]. We and others have shown that OJS reduces TNF&#945; gene expression in macrophages, as well as tissue and plasma TNF&#945; levels [<xref rid="B31-nutrients-15-01559" ref-type="bibr">31</xref>,<xref rid="B32-nutrients-15-01559" ref-type="bibr">32</xref>]. Therefore, we hypothesized that OJS decreases nociception by diminishing TNF&#945; production.</p><p>Based on our findings, we conclude that the anti-nociceptive effects of OJS are not mediated via TNF&#945; originating from macrophages. In fact, macrophage-derived TNF&#945; does not contribute to somatic referred hyperalgesia, and might play a small role in colitis development and progression. Nonetheless, others have found that TNF&#945; is an important mediator in the pathogenesis of ulcerative colitis, and it is also involved in increased neuronal excitability in dorsal root ganglia innervating the colon [<xref rid="B23-nutrients-15-01559" ref-type="bibr">23</xref>,<xref rid="B39-nutrients-15-01559" ref-type="bibr">39</xref>,<xref rid="B74-nutrients-15-01559" ref-type="bibr">74</xref>,<xref rid="B75-nutrients-15-01559" ref-type="bibr">75</xref>]. For instance, it is possible that TNF&#945; is secreted from other cells rather than macrophages, as T and B lymphocytes, epithelial, and endothelial cells can produce TNF&#945; [<xref rid="B76-nutrients-15-01559" ref-type="bibr">76</xref>,<xref rid="B77-nutrients-15-01559" ref-type="bibr">77</xref>,<xref rid="B78-nutrients-15-01559" ref-type="bibr">78</xref>,<xref rid="B79-nutrients-15-01559" ref-type="bibr">79</xref>,<xref rid="B80-nutrients-15-01559" ref-type="bibr">80</xref>]. More importantly, treatments using anti-TNF&#945; have shown to be effective early on but less effective in inducing remission in ulcerative colitis cases [<xref rid="B81-nutrients-15-01559" ref-type="bibr">81</xref>,<xref rid="B82-nutrients-15-01559" ref-type="bibr">82</xref>,<xref rid="B83-nutrients-15-01559" ref-type="bibr">83</xref>,<xref rid="B84-nutrients-15-01559" ref-type="bibr">84</xref>]. Similar to our results, De Santis et. al. showed that whole-body TNF&#945; deficiency does not influence colitis development in the Winnie mouse model of ulcerative colitis [<xref rid="B85-nutrients-15-01559" ref-type="bibr">85</xref>]. Furthermore, utilizing DSS in a whole-body TNF&#945; deletion mouse, Naito et. al., suggested that the blockage of TNF&#945; can be detrimental, as it can lead to a decrease in survival and enhance intestinal inflammation [<xref rid="B86-nutrients-15-01559" ref-type="bibr">86</xref>]. Evidence of a compensatory increase of interleukin-1&#946; in TNF&#945;-deficient Winnie mice might explain why anti-TNF&#945; therapy decreases efficacy [<xref rid="B85-nutrients-15-01559" ref-type="bibr">85</xref>]. As such it is possible that the antinociceptive effects of OJS might be caused by diminishing other IBD-associated nociceptive signals, such as transient receptor potential vanilloid 1 (TRPV1), substance P, and the calcitonin gene-related peptide (CGRP), to mention a few [<xref rid="B87-nutrients-15-01559" ref-type="bibr">87</xref>].</p><p>When administered Ojeok-san, mice displayed a more tolerant response to mechanical stimulation with von Frey filaments, as well as less aversive behavior to colorectal distension. These data suggest that the presence of OJS in the body decreases the nociceptive behaviors associated with colitis and visceral pain. Based on the data gathered, OJS administration decreases the colonic expression of calcitonin receptors, &#956;-opioid receptors, and &#954;-opioid receptors. The calcitonin receptor is the functional receptor of CGRP, which is known to mediate colonic motor responses, pain, and inflammation [<xref rid="B88-nutrients-15-01559" ref-type="bibr">88</xref>,<xref rid="B89-nutrients-15-01559" ref-type="bibr">89</xref>,<xref rid="B90-nutrients-15-01559" ref-type="bibr">90</xref>]. Previous studies have shown that deletion or blockage of the calcitonin receptor in rats with IBD (trinitrobenzene sulfonic acid, TNBS) exacerbated colonic inflammation and necrosis [<xref rid="B91-nutrients-15-01559" ref-type="bibr">91</xref>,<xref rid="B92-nutrients-15-01559" ref-type="bibr">92</xref>]. Whether the impact of OJS on calcitonin receptor expression is influencing inflammation, muscle tone, and/or nociception is not known. Regarding opioid receptors in colitis, an increased expression of &#956;-opioid receptors has been associated with a protective role against inflammation [<xref rid="B93-nutrients-15-01559" ref-type="bibr">93</xref>,<xref rid="B94-nutrients-15-01559" ref-type="bibr">94</xref>]. However, another study found no changes in &#956;-, &#948;-, and &#954;-opioid receptors in a model of colitis [<xref rid="B95-nutrients-15-01559" ref-type="bibr">95</xref>]. In our study, we did not observe an increase in histopathological inflammation or nociception in OJS-treated mice. Therefore, it is unclear as to how OJS is affecting opioid receptors.</p><p>Given that drug dependence and opioid misuse has been observed in patients with IBD [<xref rid="B13-nutrients-15-01559" ref-type="bibr">13</xref>,<xref rid="B96-nutrients-15-01559" ref-type="bibr">96</xref>,<xref rid="B97-nutrients-15-01559" ref-type="bibr">97</xref>], we screened OJS for potential abuse liability using conditioned place-preference tests. We found no differences in compartment preference between vehicle and OJS-treated mdr1a KO and IL-10 KO mice. Addictive substances such as morphine, cocaine and amphetamine have shown rewarding properties (preference for paired compartment) using the conditioned place-preference test [<xref rid="B98-nutrients-15-01559" ref-type="bibr">98</xref>,<xref rid="B99-nutrients-15-01559" ref-type="bibr">99</xref>,<xref rid="B100-nutrients-15-01559" ref-type="bibr">100</xref>]. In recent attempts to determine analgesic efficacy of drugs in animal studies, conditioned place-preference paradigms have been used, as pain relief is associated with a rewarding experience [<xref rid="B46-nutrients-15-01559" ref-type="bibr">46</xref>]. Testing analgesic efficacy with the conditioned place preference assay might bring unintended consequence, as addictive substances are extremely rewarding. Additionally, rats treated with the painkiller indomethacin failed to produce place preference [<xref rid="B46-nutrients-15-01559" ref-type="bibr">46</xref>]. Nonetheless, the use of multiple paradigms that test nociception via eliciting stimuli, spontaneous painful diseases, rewarding behavior, and aversive states might be necessary to advance pain management.</p><p>Overall, the data we gathered indicate that OJS has potential as an analgesic compound to ameliorate visceral sensitivity. However, the direct mechanism by which OJS decreases nociception associated with colitis is still unknown. Further research will be needed to determine if the effects of OJS are mediated via the peripheral or central nervous system. By continuing to research OJS, we may be able to further understand how this herbal formula works and properly apply it as a safe and reliable treatment to ameliorate pain.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank Sergei Nedospasov (Engelhardt Institute of Molecular Biology) and Sergei Grivennikov (Fox Chase Cancer Center) for providing the TNF&#945;<sup>Flox/Flox</sup> mice; Hyeun-Kyoo Shin (Director of the herbal Medicine Formulation Research Group at the Korean Institute of Oriental Medicine) for kindly gifting Ojeok-san.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-nutrients-15-01559"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/nu15071559/s1">https://www.mdpi.com/article/10.3390/nu15071559/s1</uri>, Figure S1: Macrophage deletion of TNF&#945; and Ojeok-san administration do not influence colonic TNF&#945; and IL-4 expression.</p><supplementary-material id="nutrients-15-01559-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutrients-15-01559-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, E.A.P., R.T.E. and K.T.V.; Data curation, P.C., M.N., H.P.H., G.M.-M., A.S.S., M.K.D., C.A.U., A.K.A., R.T.E., I.C. and K.T.V.; Formal analysis, E.A.P., P.C., M.N., C.A.U., R.T.E. and K.T.V.; Funding acquisition, R.T.E. and K.T.V.; Methodology, E.A.P. and K.T.V.; Project administration, K.T.V.; Resources, K.T.V.; Supervision, R.T.E., I.C. and K.T.V.; Visualization, K.T.V.; Writing&#8212;review &amp; editing, E.A.P., P.C., M.N., H.P.H., G.M.-M., A.S.S., M.K.D., C.A.U., A.K.A., R.T.E., I.C. and K.T.V. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Institutional. Animal Care and Usage Committee (IACUC) at the University of South Carolina in accordance with the American Association for Laboratory Animal Sciences (AALAS).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data regarding this work are available from the corresponding author upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-15-01559"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahlhamer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Zammitti</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Wheaton</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Croft</surname><given-names>J.B.</given-names></name></person-group><article-title>Prevalence of Inflammatory Bowel Disease Among Adults Aged &#8805;18 Years&#8212;United States, 2015</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>1166</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6542a3</pub-id><pub-id pub-id-type="pmid">27787492</pub-id></element-citation></ref><ref id="B2-nutrients-15-01559"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loftus</surname><given-names>E.V.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Update on the Incidence and Prevalence of Inflammatory Bowel Disease in the United States</article-title><source>Gastroenterol. Hepatol.</source><year>2016</year><volume>12</volume><fpage>704</fpage><lpage>707</lpage><pub-id pub-id-type="pmcid">PMC5193090</pub-id><pub-id pub-id-type="pmid">28035199</pub-id></element-citation></ref><ref id="B3-nutrients-15-01559"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aghazadeh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zali</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bahari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ghahghaie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Firouzi</surname><given-names>F.</given-names></name></person-group><article-title>Inflammatory bowel disease in Iran: A review of 457 cases</article-title><source>J. Gastroenterol. Hepatol.</source><year>2005</year><volume>20</volume><fpage>1691</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2005.03905.x</pub-id><pub-id pub-id-type="pmid">16246187</pub-id></element-citation></ref><ref id="B4-nutrients-15-01559"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagtmans</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Verspaget</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Lamers</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>van Hogezand</surname><given-names>R.A.</given-names></name></person-group><article-title>Crohn&#8217;s disease in the elderly: A comparison with young adults</article-title><source>J. Clin. Gastroenterol.</source><year>1998</year><volume>27</volume><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1097/00004836-199809000-00005</pub-id><pub-id pub-id-type="pmid">9754773</pub-id></element-citation></ref><ref id="B5-nutrients-15-01559"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Fikri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Libbrecht</surname><given-names>D.</given-names></name><name name-style="western"><surname>Louis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Joris</surname><given-names>J.</given-names></name></person-group><article-title>Pain Characteristics in Patients with Inflammatory Bowel Disease: A Monocentric Cross-Sectional Study</article-title><source>J. Crohns Colitis</source><year>2022</year><volume>16</volume><fpage>1363</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjac051</pub-id><pub-id pub-id-type="pmid">35380673</pub-id></element-citation></ref><ref id="B6-nutrients-15-01559"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bielefeldt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Binion</surname><given-names>D.G.</given-names></name></person-group><article-title>Pain and inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2009</year><volume>15</volume><fpage>778</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1002/ibd.20848</pub-id><pub-id pub-id-type="pmid">19130619</pub-id><pub-id pub-id-type="pmcid">PMC3180862</pub-id></element-citation></ref><ref id="B7-nutrients-15-01559"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardizzone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cassinotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duca</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mazzali</surname><given-names>C.</given-names></name><name name-style="western"><surname>Penati</surname><given-names>C.</given-names></name><name name-style="western"><surname>Manes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marmo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Massari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Molteni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maconi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2011</year><volume>9</volume><fpage>483</fpage><lpage>489.e3</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2010.12.028</pub-id><pub-id pub-id-type="pmid">21195796</pub-id></element-citation></ref><ref id="B8-nutrients-15-01559"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilar</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Carpi</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Acuna</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Masiques</surname><given-names>M.A.</given-names></name></person-group><article-title>Infliximab in paediatric inflammatory bowel disease</article-title><source>J. Crohns Colitis</source><year>2007</year><volume>1</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2007.07.001</pub-id><pub-id pub-id-type="pmid">21172178</pub-id></element-citation></ref><ref id="B9-nutrients-15-01559"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Staa</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Card</surname><given-names>T.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Leufkens</surname><given-names>H.G.</given-names></name></person-group><article-title>5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: A large epidemiological study</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>1573</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1136/gut.2005.070896</pub-id><pub-id pub-id-type="pmid">15994215</pub-id><pub-id pub-id-type="pmcid">PMC1774734</pub-id></element-citation></ref><ref id="B10-nutrients-15-01559"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matuk</surname><given-names>R.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Targan</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Vasiliauskas</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Papadakis</surname><given-names>K.A.</given-names></name></person-group><article-title>The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease</article-title><source>Inflamm. Bowel Dis.</source><year>2004</year><volume>10</volume><fpage>352</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1097/00054725-200407000-00005</pub-id><pub-id pub-id-type="pmid">15475742</pub-id></element-citation></ref><ref id="B11-nutrients-15-01559"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smale</surname><given-names>S.</given-names></name><name name-style="western"><surname>Premchand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maiden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thjodleifsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bjornsson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bjarnason</surname><given-names>I.</given-names></name></person-group><article-title>Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2006</year><volume>4</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(05)00980-8</pub-id><pub-id pub-id-type="pmid">16469680</pub-id></element-citation></ref><ref id="B12-nutrients-15-01559"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Radford-Smith</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Florin</surname><given-names>T.H.</given-names></name></person-group><article-title>Chronic narcotic use in inflammatory bowel disease patients: Prevalence and clinical characteristics</article-title><source>J. Gastroenterol. Hepatol.</source><year>2001</year><volume>16</volume><fpage>1235</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1746.2001.02468.x</pub-id><pub-id pub-id-type="pmid">11903741</pub-id></element-citation></ref><ref id="B13-nutrients-15-01559"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Korelitz</surname><given-names>B.I.</given-names></name></person-group><article-title>Narcotic dependence in inflammatory bowel disease</article-title><source>J. Clin. Gastroenterol.</source><year>1988</year><volume>10</volume><fpage>275</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1097/00004836-198806000-00010</pub-id><pub-id pub-id-type="pmid">2980762</pub-id></element-citation></ref><ref id="B14-nutrients-15-01559"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Binion</surname><given-names>D.G.</given-names></name></person-group><article-title>Narcotic use in patients with Crohn&#8217;s disease</article-title><source>Am. J. Gastroenterol.</source><year>2005</year><volume>100</volume><fpage>2225</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00256.x</pub-id><pub-id pub-id-type="pmid">16181373</pub-id></element-citation></ref><ref id="B15-nutrients-15-01559"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtenstein</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Feagan</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sandborn</surname><given-names>W.J.</given-names></name></person-group><article-title>Serious infections and mortality in association with therapies for Crohn&#8217;s disease: TREAT registry</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2006</year><volume>4</volume><fpage>621</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2006.03.002</pub-id><pub-id pub-id-type="pmid">16678077</pub-id></element-citation></ref><ref id="B16-nutrients-15-01559"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nathan</surname><given-names>C.F.</given-names></name></person-group><article-title>Secretory products of macrophages</article-title><source>J. Clin. Investig.</source><year>1987</year><volume>79</volume><fpage>319</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1172/JCI112815</pub-id><pub-id pub-id-type="pmid">3543052</pub-id><pub-id pub-id-type="pmcid">PMC424063</pub-id></element-citation></ref><ref id="B17-nutrients-15-01559"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Scheff</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Dubeykovskaya</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Chavan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Aouizerat</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name></person-group><article-title>TNFalpha promotes oral cancer growth, pain, and Schwann cell activation</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>1840</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-81500-4</pub-id><pub-id pub-id-type="pmid">33469141</pub-id><pub-id pub-id-type="pmcid">PMC7815837</pub-id></element-citation></ref><ref id="B18-nutrients-15-01559"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Obeed</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Alkhayal</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Al Sheikh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zubaidi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vaali-Mohammed</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Boushey</surname><given-names>R.</given-names></name><name name-style="western"><surname>McKerrow</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>M.H.</given-names></name></person-group><article-title>Increased expression of tumor necrosis factor-alpha is associated with advanced colorectal cancer stages</article-title><source>World J. Gastroenterol.</source><year>2014</year><volume>20</volume><fpage>18390</fpage><lpage>18396</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i48.18390</pub-id><pub-id pub-id-type="pmid">25561807</pub-id><pub-id pub-id-type="pmcid">PMC4277977</pub-id></element-citation></ref><ref id="B19-nutrients-15-01559"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enos</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Velazquez</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>McClellan</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cranford</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Nagarkatti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagarkatti</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>E.A.</given-names></name></person-group><article-title>High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2016</year><volume>310</volume><fpage>G906</fpage><lpage>G919</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00345.2015</pub-id><pub-id pub-id-type="pmid">27033117</pub-id><pub-id pub-id-type="pmcid">PMC4935479</pub-id></element-citation></ref><ref id="B20-nutrients-15-01559"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velazquez</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Enos</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>McClellan</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cranford</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Chatzistamou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>U.P.</given-names></name><name name-style="western"><surname>Nagarkatti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagarkatti</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>E.A.</given-names></name></person-group><article-title>MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2016</year><volume>310</volume><fpage>G347</fpage><lpage>G358</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00326.2015</pub-id><pub-id pub-id-type="pmid">26744471</pub-id><pub-id pub-id-type="pmcid">PMC4796295</pub-id></element-citation></ref><ref id="B21-nutrients-15-01559"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>K.R.</given-names></name></person-group><article-title>TNF-alpha-induced intestinal epithelial cell shedding: Implications for intestinal barrier function</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2012</year><volume>1258</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06523.x</pub-id><pub-id pub-id-type="pmid">22731709</pub-id></element-citation></ref><ref id="B22-nutrients-15-01559"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leppkes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roulis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Kollias</surname><given-names>G.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C.</given-names></name></person-group><article-title>Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation</article-title><source>Int. Immunol.</source><year>2014</year><volume>26</volume><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxu051</pub-id><pub-id pub-id-type="pmid">24821262</pub-id></element-citation></ref><ref id="B23-nutrients-15-01559"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sands</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>G.G.</given-names></name></person-group><article-title>The role of TNFalpha in ulcerative colitis</article-title><source>J. Clin. Pharmacol.</source><year>2007</year><volume>47</volume><fpage>930</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1177/0091270007301623</pub-id><pub-id pub-id-type="pmid">17567930</pub-id></element-citation></ref><ref id="B24-nutrients-15-01559"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.K.</given-names></name></person-group><article-title>Genotoxicity assessment of a herbal formula, Ojeok-san</article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>135</volume><fpage>586</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.03.024</pub-id><pub-id pub-id-type="pmid">21419208</pub-id></element-citation></ref><ref id="B25-nutrients-15-01559"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Watson</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Preedy</surname><given-names>V.R.</given-names></name></person-group><source>Botanical Medicine in Clinical Practice</source><publisher-name>CABI</publisher-name><publisher-loc>Oxfordshire, UK</publisher-loc><year>2008</year><fpage>915</fpage></element-citation></ref><ref id="B26-nutrients-15-01559"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ha</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.K.</given-names></name></person-group><article-title>Evaluation of safety of the herbal formula Ojeok-san: Acute and sub-chronic toxicity studies in rats</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>131</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.07.011</pub-id><pub-id pub-id-type="pmid">20633626</pub-id></element-citation></ref><ref id="B27-nutrients-15-01559"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.K.</given-names></name></person-group><article-title>Cytotoxicity and sub-acute toxicity in Crl:CD (SD) rats of traditional herbal formula Ojeok-san</article-title><source>BMC Complement. Altern. Med.</source><year>2015</year><volume>15</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-015-0582-y</pub-id><pub-id pub-id-type="pmid">25888080</pub-id><pub-id pub-id-type="pmcid">PMC4354991</pub-id></element-citation></ref><ref id="B28-nutrients-15-01559"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.S.</given-names></name></person-group><article-title>Study to establish Ojeok-San (Five Accumulation Powder: Wu ji san) administration criteria and a questionnaire to evaluate the holistic effects of Ojeok-San on patients with low back pain</article-title><source>J. Altern. Complement. Med.</source><year>2013</year><volume>19</volume><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1089/acm.2011.0312</pub-id><pub-id pub-id-type="pmid">23373442</pub-id></element-citation></ref><ref id="B29-nutrients-15-01559"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.K.</given-names></name></person-group><article-title>Compositional Differences of Ojeok-san (Wuji-san) Decoctions Using Pressurized or Non-pressurized Methods for Variable Extraction Times</article-title><source>J. Pharmacopunct.</source><year>2012</year><volume>15</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3831/KPI.2012.15.2.024</pub-id><pub-id pub-id-type="pmid">25780639</pub-id><pub-id pub-id-type="pmcid">PMC4331933</pub-id></element-citation></ref><ref id="B30-nutrients-15-01559"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weon</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.J.</given-names></name></person-group><article-title>Simultaneous quantification of marker components in Ojeok-san by HPLC-DAD</article-title><source>J. Nat. Med.</source><year>2011</year><volume>65</volume><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1007/s11418-010-0494-6</pub-id><pub-id pub-id-type="pmid">21188642</pub-id></element-citation></ref><ref id="B31-nutrients-15-01559"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sumal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>E.</given-names></name><name name-style="western"><surname>Helms</surname><given-names>H.</given-names></name><name name-style="western"><surname>Noneman</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Martinez-Muniz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chatzistamou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aladhami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Unger</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Ojeok-san ameliorates visceral and somatic nociception in a mouse model of colitis induced colorectal cancer</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0270338</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0270338</pub-id><pub-id pub-id-type="pmid">35737651</pub-id><pub-id pub-id-type="pmcid">PMC9223640</pub-id></element-citation></ref><ref id="B32-nutrients-15-01559"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name></person-group><article-title>Effects of Ojeoksangamibang Extract on the Recovery of Liver Function in CCl 4-exposed Rats</article-title><source>J. Korean Med. Rehabil.</source><year>2013</year><volume>23</volume><fpage>45</fpage><lpage>53</lpage></element-citation></ref><ref id="B33-nutrients-15-01559"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.H.</given-names></name></person-group><article-title>Activation of Immune System &amp; Antimetastatic Effects of Ojeok-san by Oral Administration</article-title><source>J. Korean Obstet. Gynecol.</source><year>2014</year><volume>27</volume><fpage>34</fpage><lpage>45</lpage></element-citation></ref><ref id="B34-nutrients-15-01559"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>H.K.</given-names></name><etal/></person-group><article-title>Effects of water and ethanol extracts from Ojeok-san on inflammation and its related diseases</article-title><source>J. Intern. Korean Med.</source><year>2012</year><volume>33</volume><fpage>418</fpage><lpage>428</lpage></element-citation></ref><ref id="B35-nutrients-15-01559"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Eun</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>The Inhibitory Effect of Ojeoksan on Early and Advanced Atherosclerosis</article-title><source>Nutrients</source><year>2018</year><volume>10</volume><elocation-id>1256</elocation-id><pub-id pub-id-type="doi">10.3390/nu10091256</pub-id><pub-id pub-id-type="pmid">30200674</pub-id><pub-id pub-id-type="pmcid">PMC6164175</pub-id></element-citation></ref><ref id="B36-nutrients-15-01559"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ham</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>B.I.</given-names></name></person-group><article-title>Anti-inflammatory Effects of Ojeok-san in LPS-induced Inflammatory Rat Model</article-title><source>J. Korean Med.</source><year>2021</year><volume>42</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.13048/jkm.21012</pub-id></element-citation></ref><ref id="B37-nutrients-15-01559"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oshitani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>T.</given-names></name></person-group><article-title>Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease</article-title><source>Int. J. Mol. Med.</source><year>2003</year><volume>11</volume><fpage>175</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.3892/ijmm.11.2.175</pub-id><pub-id pub-id-type="pmid">12525873</pub-id></element-citation></ref><ref id="B38-nutrients-15-01559"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Heel</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Udalova</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>De Silva</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>McGovern</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Kinouchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hull</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lench</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Cardon</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>D.P.</given-names></name><etal/></person-group><article-title>Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors</article-title><source>Hum. Mol. Genet.</source><year>2002</year><volume>11</volume><fpage>1281</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.11.1281</pub-id><pub-id pub-id-type="pmid">12019209</pub-id></element-citation></ref><ref id="B39-nutrients-15-01559"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>S.</given-names></name></person-group><article-title>Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase</article-title><source>J. Clin. Lab. Immunol.</source><year>1995</year><volume>46</volume><fpage>111</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">8926619</pub-id></element-citation></ref><ref id="B40-nutrients-15-01559"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutgeerts</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sandborn</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Feagan</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Reinisch</surname><given-names>W.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johanns</surname><given-names>J.</given-names></name><name name-style="western"><surname>Travers</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rachmilewitz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanauer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Lichtenstein</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Infliximab for induction and maintenance therapy for ulcerative colitis</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>2462</fpage><lpage>2476</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050516</pub-id><pub-id pub-id-type="pmid">16339095</pub-id></element-citation></ref><ref id="B41-nutrients-15-01559"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aladhami</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Unger</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>M.C.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Velazquez</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Enos</surname><given-names>R.T.</given-names></name></person-group><article-title>Macrophage tumor necrosis factor-alpha deletion does not protect against obesity-associated metabolic dysfunction</article-title><source>FASEB J.</source><year>2021</year><volume>35</volume><fpage>e21665</fpage><pub-id pub-id-type="doi">10.1096/fj.202100543RR</pub-id><pub-id pub-id-type="pmid">34131955</pub-id><pub-id pub-id-type="pmcid">PMC8716064</pub-id></element-citation></ref><ref id="B42-nutrients-15-01559"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grivennikov</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Tumanov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Liepinsh</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kruglov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Marakusha</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Shakhov</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Drutskaya</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>I.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>B.E.</given-names></name><etal/></person-group><article-title>Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: Protective and deleterious effects</article-title><source>Immunity</source><year>2005</year><volume>22</volume><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2004.11.016</pub-id><pub-id pub-id-type="pmid">15664162</pub-id></element-citation></ref><ref id="B43-nutrients-15-01559"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausen</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reith</surname><given-names>W.</given-names></name><name name-style="western"><surname>Renkawitz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>I.</given-names></name></person-group><article-title>Conditional gene targeting in macrophages and granulocytes using LysMcre mice</article-title><source>Transgenic Res.</source><year>1999</year><volume>8</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1023/A:1008942828960</pub-id><pub-id pub-id-type="pmid">10621974</pub-id></element-citation></ref><ref id="B44-nutrients-15-01559"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schinkel</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>van Tellingen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Wagenaar</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Deemter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mol</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Robanus-Maandag</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>te Riele</surname><given-names>H.P.</given-names></name><etal/></person-group><article-title>Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs</article-title><source>Cell</source><year>1994</year><volume>77</volume><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90212-7</pub-id><pub-id pub-id-type="pmid">7910522</pub-id></element-citation></ref><ref id="B45-nutrients-15-01559"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panwala</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Viney</surname><given-names>J.L.</given-names></name></person-group><article-title>A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis</article-title><source>J. Immunol.</source><year>1998</year><volume>161</volume><fpage>5733</fpage><lpage>5744</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.161.10.5733</pub-id><pub-id pub-id-type="pmid">9820555</pub-id></element-citation></ref><ref id="B46-nutrients-15-01559"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sufka</surname><given-names>K.J.</given-names></name></person-group><article-title>Conditioned place preference paradigm: A novel approach for analgesic drug assessment against chronic pain</article-title><source>Pain</source><year>1994</year><volume>58</volume><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(94)90130-9</pub-id><pub-id pub-id-type="pmid">7838585</pub-id></element-citation></ref><ref id="B47-nutrients-15-01559"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lohler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rennick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rajewsky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>W.</given-names></name></person-group><article-title>Interleukin-10-deficient mice develop chronic enterocolitis</article-title><source>Cell</source><year>1993</year><volume>75</volume><fpage>263</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)80068-P</pub-id><pub-id pub-id-type="pmid">8402911</pub-id></element-citation></ref><ref id="B48-nutrients-15-01559"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderwall</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Noor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.O.</given-names></name><name name-style="western"><surname>Jantzie</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Mellios</surname><given-names>N.</given-names></name><name name-style="western"><surname>Milligan</surname><given-names>E.D.</given-names></name></person-group><article-title>Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues</article-title><source>Brain Behav. Immun.</source><year>2018</year><volume>69</volume><fpage>91</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2017.11.004</pub-id><pub-id pub-id-type="pmid">29113923</pub-id><pub-id pub-id-type="pmcid">PMC5857419</pub-id></element-citation></ref><ref id="B49-nutrients-15-01559"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Bobinski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Kolker</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sluka</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A.R.</given-names></name></person-group><article-title>IL-10 cytokine released from M2 macrophages is crucial for analgesic and anti-inflammatory effects of acupuncture in a model of inflammatory muscle pain</article-title><source>Mol. Neurobiol.</source><year>2015</year><volume>51</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1007/s12035-014-8790-x</pub-id><pub-id pub-id-type="pmid">24961568</pub-id><pub-id pub-id-type="pmcid">PMC4276737</pub-id></element-citation></ref><ref id="B50-nutrients-15-01559"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mietto</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kroner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Girolami</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Santos-Nogueira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>David</surname><given-names>S.</given-names></name></person-group><article-title>Role of IL-10 in Resolution of Inflammation and Functional Recovery after Peripheral Nerve Injury</article-title><source>J. Neurosci.</source><year>2015</year><volume>35</volume><fpage>16431</fpage><lpage>16442</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2119-15.2015</pub-id><pub-id pub-id-type="pmid">26674868</pub-id><pub-id pub-id-type="pmcid">PMC6605511</pub-id></element-citation></ref><ref id="B51-nutrients-15-01559"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krukowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eijkelkamp</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laumet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hack</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dougherty</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Heijnen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Kavelaars</surname><given-names>A.</given-names></name></person-group><article-title>CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain</article-title><source>J. Neurosci.</source><year>2016</year><volume>36</volume><fpage>11074</fpage><lpage>11083</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3708-15.2016</pub-id><pub-id pub-id-type="pmid">27798187</pub-id><pub-id pub-id-type="pmcid">PMC5098842</pub-id></element-citation></ref><ref id="B52-nutrients-15-01559"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamp</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.C.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Tillman</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G.F.</given-names></name></person-group><article-title>Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2003</year><volume>284</volume><fpage>G434</fpage><lpage>G444</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00324.2002</pub-id><pub-id pub-id-type="pmid">12444012</pub-id></element-citation></ref><ref id="B53-nutrients-15-01559"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Basso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cenac</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blanpied</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rolli-Derkinderen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neunlist</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vergnolle</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>G.</given-names></name></person-group><article-title>Endogenous regulation of visceral pain via production of opioids by colitogenic CD4(+) T cells in mice</article-title><source>Gastroenterology</source><year>2014</year><volume>146</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.09.020</pub-id><pub-id pub-id-type="pmid">24055279</pub-id></element-citation></ref><ref id="B54-nutrients-15-01559"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erben</surname><given-names>U.</given-names></name><name name-style="western"><surname>Loddenkemper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doerfel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Spieckermann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heimesaat</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zeitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siegmund</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuhl</surname><given-names>A.A.</given-names></name></person-group><article-title>A guide to histomorphological evaluation of intestinal inflammation in mouse models</article-title><source>Int. J. Clin. Exp. Pathol.</source><year>2014</year><volume>7</volume><fpage>4557</fpage><lpage>4576</lpage><pub-id pub-id-type="pmid">25197329</pub-id><pub-id pub-id-type="pmcid">PMC4152019</pub-id></element-citation></ref><ref id="B55-nutrients-15-01559"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viennois</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Laroui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Merlin</surname><given-names>D.</given-names></name></person-group><article-title>Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: Lithium chloride purification, a rapid and efficient technique to purify RNA</article-title><source>BMC Res. Notes</source><year>2013</year><volume>6</volume><elocation-id>360</elocation-id><pub-id pub-id-type="doi">10.1186/1756-0500-6-360</pub-id><pub-id pub-id-type="pmid">24010775</pub-id><pub-id pub-id-type="pmcid">PMC3847706</pub-id></element-citation></ref><ref id="B56-nutrients-15-01559"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ness</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G.F.</given-names></name></person-group><article-title>Colorectal distension as a noxious visceral stimulus: Physiologic and pharmacologic characterization of pseudaffective reflexes in the rat</article-title><source>Brain Res.</source><year>1988</year><volume>450</volume><fpage>153</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(88)91555-7</pub-id><pub-id pub-id-type="pmid">3401708</pub-id></element-citation></ref><ref id="B57-nutrients-15-01559"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Mahony</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tramullas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cryan</surname><given-names>J.F.</given-names></name></person-group><article-title>Rodent models of colorectal distension</article-title><source>Curr. Protoc. Neurosci.</source><year>2012</year><volume>61</volume><fpage>9</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/0471142301.ns0940s61</pub-id><pub-id pub-id-type="pmid">23093353</pub-id></element-citation></ref><ref id="B58-nutrients-15-01559"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christianson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G.F.</given-names></name></person-group><article-title>Assessment of colon sensitivity by luminal distension in mice</article-title><source>Nat. Protoc.</source><year>2007</year><volume>2</volume><fpage>2624</fpage><lpage>2631</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.392</pub-id><pub-id pub-id-type="pmid">17948005</pub-id></element-citation></ref><ref id="B59-nutrients-15-01559"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arvidsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lindstrom</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>V.</given-names></name></person-group><article-title>Assessment of visceral pain-related pseudo-affective responses to colorectal distension in mice by intracolonic manometric recordings</article-title><source>J. Pain</source><year>2006</year><volume>7</volume><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2005.09.003</pub-id><pub-id pub-id-type="pmid">16459276</pub-id></element-citation></ref><ref id="B60-nutrients-15-01559"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ness</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Metcalf</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G.F.</given-names></name></person-group><article-title>A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus</article-title><source>Pain</source><year>1990</year><volume>43</volume><fpage>377</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(90)90035-C</pub-id><pub-id pub-id-type="pmid">2293146</pub-id></element-citation></ref><ref id="B61-nutrients-15-01559"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nocerino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lakhani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Swaminath</surname><given-names>A.</given-names></name></person-group><article-title>Fatigue in Inflammatory Bowel Diseases: Etiologies and Management</article-title><source>Adv. Ther.</source><year>2020</year><volume>37</volume><fpage>97</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1007/s12325-019-01151-w</pub-id><pub-id pub-id-type="pmid">31760611</pub-id><pub-id pub-id-type="pmcid">PMC6979464</pub-id></element-citation></ref><ref id="B62-nutrients-15-01559"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szigethy</surname><given-names>E.</given-names></name></person-group><article-title>Pain Management in Patients With Inflammatory Bowel Disease</article-title><source>Gastroenterol. Hepatol.</source><year>2018</year><volume>14</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="pmcid">PMC5824598</pub-id><pub-id pub-id-type="pmid">29491764</pub-id></element-citation></ref><ref id="B63-nutrients-15-01559"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muller-Mottet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scharl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biedermann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Scharl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fried</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0156666</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0156666</pub-id><pub-id pub-id-type="pmid">27332879</pub-id><pub-id pub-id-type="pmcid">PMC4917102</pub-id></element-citation></ref><ref id="B64-nutrients-15-01559"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Takakura</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bresee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melmed</surname><given-names>G.Y.</given-names></name></person-group><article-title>Pain in Inflammatory Bowel Disease Is Not Improved During Hospitalization: The Impact of Opioids on Pain and Healthcare Utilization</article-title><source>Dig. Dis. Sci.</source><year>2020</year><volume>65</volume><fpage>1777</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1007/s10620-019-05906-x</pub-id><pub-id pub-id-type="pmid">31654314</pub-id></element-citation></ref><ref id="B65-nutrients-15-01559"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Bielefeldt</surname><given-names>K.</given-names></name></person-group><article-title>Experimental colitis in mice and sensitization of converging visceral and somatic afferent pathways</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2006</year><volume>290</volume><fpage>G451</fpage><lpage>G457</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00353.2005</pub-id><pub-id pub-id-type="pmid">16195421</pub-id></element-citation></ref><ref id="B66-nutrients-15-01559"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delafoy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gelot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ardid</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eschalier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Diop</surname><given-names>L.</given-names></name></person-group><article-title>Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>940</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1136/gut.2005.064063</pub-id><pub-id pub-id-type="pmid">16401692</pub-id><pub-id pub-id-type="pmcid">PMC1856334</pub-id></element-citation></ref><ref id="B67-nutrients-15-01559"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eijkelkamp</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kavelaars</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elsenbruch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schedlowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holtmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heijnen</surname><given-names>C.J.</given-names></name></person-group><article-title>Increased visceral sensitivity to capsaicin after DSS-induced colitis in mice: Spinal cord c-Fos expression and behavior</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2007</year><volume>293</volume><fpage>G749</fpage><lpage>G757</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00114.2007</pub-id><pub-id pub-id-type="pmid">17656446</pub-id></element-citation></ref><ref id="B68-nutrients-15-01559"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gross</surname><given-names>V.</given-names></name><name name-style="western"><surname>Andus</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leser</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scholmerich</surname><given-names>J.</given-names></name></person-group><article-title>Inflammatory mediators in chronic inflammatory bowel diseases</article-title><source>Klin. Wochenschr.</source><year>1991</year><volume>69</volume><fpage>981</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1007/BF01645143</pub-id><pub-id pub-id-type="pmid">1798295</pub-id></element-citation></ref><ref id="B69-nutrients-15-01559"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powrie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>M.W.</given-names></name></person-group><article-title>Genetic and spontaneous models of inflammatory bowel disease in rodents: Evidence for abnormalities in mucosal immune regulation</article-title><source>Ther. Immunol.</source><year>1995</year><volume>2</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">8729882</pub-id></element-citation></ref><ref id="B70-nutrients-15-01559"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gereau</surname><given-names>R.W.T.</given-names></name></person-group><article-title>Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha</article-title><source>J. Neurosci.</source><year>2006</year><volume>26</volume><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3858-05.2006</pub-id><pub-id pub-id-type="pmid">16399694</pub-id><pub-id pub-id-type="pmcid">PMC6674296</pub-id></element-citation></ref><ref id="B71-nutrients-15-01559"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Juelich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Rady</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>T.K.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Evidence for endogenous interleukin-10 during nociception</article-title><source>J. Neuroimmunol.</source><year>2003</year><volume>139</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(03)00126-7</pub-id><pub-id pub-id-type="pmid">12799032</pub-id></element-citation></ref><ref id="B72-nutrients-15-01559"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lindstrom</surname><given-names>E.</given-names></name></person-group><article-title>Effect of DSS-induced colitis on visceral sensitivity to colorectal distension in mice</article-title><source>Neurogastroenterol. Motil.</source><year>2006</year><volume>18</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2982.2005.00736.x</pub-id><pub-id pub-id-type="pmid">16420293</pub-id></element-citation></ref><ref id="B73-nutrients-15-01559"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benamar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mas-Orea</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deraison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blanpied</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cenac</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saoudi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>G.</given-names></name></person-group><article-title>Endogenous control of inflammatory visceral pain by T cell-derived opioids in IL-10-deficient mice</article-title><source>Neurogastroenterol. Motil.</source><year>2020</year><volume>32</volume><fpage>e13743</fpage><pub-id pub-id-type="doi">10.1111/nmo.13743</pub-id><pub-id pub-id-type="pmid">31588671</pub-id></element-citation></ref><ref id="B74-nutrients-15-01559"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibeakanma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vanner</surname><given-names>S.</given-names></name></person-group><article-title>TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>612</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.190439</pub-id><pub-id pub-id-type="pmid">20427396</pub-id></element-citation></ref><ref id="B75-nutrients-15-01559"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinecker</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Witthoeft</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pflueger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacDermott</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Raedler</surname><given-names>A.</given-names></name></person-group><article-title>Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn&#8217;s disease</article-title><source>Clin. Exp. Immunol.</source><year>1993</year><volume>94</volume><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">8403503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2249.1993.tb05997.x</pub-id><pub-id pub-id-type="pmcid">PMC1534387</pub-id></element-citation></ref><ref id="B76-nutrients-15-01559"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Long</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>TNF-alpha-secreting B cells contribute to myocardial fibrosis in dilated cardiomyopathy</article-title><source>J. Clin. Immunol.</source><year>2013</year><volume>33</volume><fpage>1002</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1007/s10875-013-9889-y</pub-id><pub-id pub-id-type="pmid">23558825</pub-id></element-citation></ref><ref id="B77-nutrients-15-01559"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rimoldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chieppa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salucci</surname><given-names>V.</given-names></name><name name-style="western"><surname>Avogadri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sonzogni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sampietro</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Nespoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Viale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rescigno</surname><given-names>M.</given-names></name></person-group><article-title>Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells</article-title><source>Nat. Immunol.</source><year>2005</year><volume>6</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/ni1192</pub-id><pub-id pub-id-type="pmid">15821737</pub-id></element-citation></ref><ref id="B78-nutrients-15-01559"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Eckmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Panja</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fierer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morzycka-Wroblewska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kagnoff</surname><given-names>M.F.</given-names></name></person-group><article-title>A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion</article-title><source>J. Clin. Investig.</source><year>1995</year><volume>95</volume><fpage>55</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1172/JCI117676</pub-id><pub-id pub-id-type="pmid">7814646</pub-id><pub-id pub-id-type="pmcid">PMC295369</pub-id></element-citation></ref><ref id="B79-nutrients-15-01559"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinus</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Goldsbury</surname><given-names>J.</given-names></name></person-group><article-title>Endothelial TNF-alpha induction by Hsp60 secreted from THP-1 monocytes exposed to hyperglycaemic conditions</article-title><source>Cell Stress Chaperones</source><year>2018</year><volume>23</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1007/s12192-017-0858-x</pub-id><pub-id pub-id-type="pmid">29134442</pub-id><pub-id pub-id-type="pmcid">PMC6045554</pub-id></element-citation></ref><ref id="B80-nutrients-15-01559"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jevnikar</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Maslinski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wuthrich</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Glimcher</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>V.E.</given-names></name></person-group><article-title>Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha</article-title><source>Kidney Int.</source><year>1991</year><volume>40</volume><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/ki.1991.201</pub-id><pub-id pub-id-type="pmid">1942768</pub-id></element-citation></ref><ref id="B81-nutrients-15-01559"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Horin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chowers</surname><given-names>Y.</given-names></name></person-group><article-title>Tailoring anti-TNF therapy in IBD: Drug levels and disease activity</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2014</year><volume>11</volume><fpage>243</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">24393836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrgastro.2013.253</pub-id></element-citation></ref><ref id="B82-nutrients-15-01559"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerra</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bermejo</surname><given-names>F.</given-names></name></person-group><article-title>Management of inflammatory bowel disease in poor responders to infliximab</article-title><source>Clin. Exp. Gastroenterol.</source><year>2014</year><volume>7</volume><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">25258548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CEG.S45297</pub-id><pub-id pub-id-type="pmcid">PMC4171998</pub-id></element-citation></ref><ref id="B83-nutrients-15-01559"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Noman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermeire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Assche</surname><given-names>G.</given-names></name><name name-style="western"><surname>D&#8217;Haens</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carbonez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rutgeerts</surname><given-names>P.</given-names></name></person-group><article-title>Influence of immunogenicity on the long-term efficacy of infliximab in Crohn&#8217;s disease</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020888</pub-id><pub-id pub-id-type="pmid">12584368</pub-id></element-citation></ref><ref id="B84-nutrients-15-01559"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papamichael</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheifetz</surname><given-names>A.S.</given-names></name></person-group><article-title>Use of anti-TNF drug levels to optimise patient management</article-title><source>Frontline Gastroenterol.</source><year>2016</year><volume>7</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1136/flgastro-2016-100685</pub-id><pub-id pub-id-type="pmid">28839870</pub-id><pub-id pub-id-type="pmcid">PMC5369499</pub-id></element-citation></ref><ref id="B85-nutrients-15-01559"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Santis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kunde</surname><given-names>D.</given-names></name><name name-style="western"><surname>Galleggiante</surname><given-names>V.</given-names></name><name name-style="western"><surname>Liso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scandiffio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Serino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campiglia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sorrentino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cavalcanti</surname><given-names>E.</given-names></name><etal/></person-group><article-title>TNFalpha deficiency results in increased IL-1beta in an early onset of spontaneous murine colitis</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2993</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.397</pub-id><pub-id pub-id-type="pmid">28796256</pub-id><pub-id pub-id-type="pmcid">PMC5596580</pub-id></element-citation></ref><ref id="B86-nutrients-15-01559"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takagi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Handa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>N.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Imanishi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice</article-title><source>J. Gastroenterol. Hepatol.</source><year>2003</year><volume>18</volume><fpage>560</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1746.2003.03034.x</pub-id><pub-id pub-id-type="pmid">12702049</pub-id></element-citation></ref><ref id="B87-nutrients-15-01559"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrell</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Callister</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Keely</surname><given-names>S.</given-names></name></person-group><article-title>Understanding and targeting centrally mediated visceral pain in inflammatory bowel disease</article-title><source>Front. Pharmacol.</source><year>2014</year><volume>5</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.3389/fphar.2014.00027</pub-id><pub-id pub-id-type="pmid">24634658</pub-id><pub-id pub-id-type="pmcid">PMC3942649</pub-id></element-citation></ref><ref id="B88-nutrients-15-01559"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>P.</given-names></name><name name-style="western"><surname>Black</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keane</surname><given-names>V.</given-names></name><name name-style="western"><surname>Snow</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rigney</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Magder</surname><given-names>L.</given-names></name></person-group><article-title>Risk factors for disruption in primary caregiving among infants of substance abusing women</article-title><source>Child Abus. Negl.</source><year>1997</year><volume>21</volume><fpage>1039</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1016/S0145-2134(97)00064-1</pub-id><pub-id pub-id-type="pmid">9422825</pub-id><pub-id pub-id-type="pmcid">PMC3141823</pub-id></element-citation></ref><ref id="B89-nutrients-15-01559"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holzer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bartho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Matusak</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>V.</given-names></name></person-group><article-title>Calcitonin gene-related peptide action on intestinal circular muscle</article-title><source>Am. J. Physiol.</source><year>1989</year><volume>256</volume><issue-part>Pt 1</issue-part><fpage>G546</fpage><lpage>G552</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.1989.256.3.G546</pub-id><pub-id pub-id-type="pmid">2564254</pub-id></element-citation></ref><ref id="B90-nutrients-15-01559"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eysselein</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Reinshagen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cominelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sternini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>W.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nast</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Calcitonin gene-related peptide and substance P decrease in the rabbit colon during colitis. A time study</article-title><source>Gastroenterology</source><year>1991</year><volume>101</volume><fpage>1211</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(91)90069-W</pub-id><pub-id pub-id-type="pmid">1718806</pub-id></element-citation></ref><ref id="B91-nutrients-15-01559"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clifton</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hoy</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Idumalla</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Fakhruddin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Grady</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Dada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corvera</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>A.</given-names></name></person-group><article-title>Role of calcitonin receptor-like receptor in colonic motility and inflammation</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2007</year><volume>293</volume><fpage>G36</fpage><lpage>G44</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00464.2006</pub-id><pub-id pub-id-type="pmid">17363466</pub-id></element-citation></ref><ref id="B92-nutrients-15-01559"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazelin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Theodorou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fioramonti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>L.</given-names></name></person-group><article-title>Vagally dependent protective action of calcitonin gene-related peptide on colitis</article-title><source>Peptides</source><year>1999</year><volume>20</volume><fpage>1367</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1016/S0196-9781(99)00144-8</pub-id><pub-id pub-id-type="pmid">10612453</pub-id></element-citation></ref><ref id="B93-nutrients-15-01559"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anselmi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duraffourd</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jaramillo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vegezzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Saccani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boschetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brecha</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>De Giorgio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sternini</surname><given-names>C.</given-names></name></person-group><article-title>Activation of mu opioid receptors modulates inflammation in acute experimental colitis</article-title><source>Neurogastroenterol. Motil.</source><year>2015</year><volume>27</volume><fpage>509</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1111/nmo.12521</pub-id><pub-id pub-id-type="pmid">25690069</pub-id><pub-id pub-id-type="pmcid">PMC4405133</pub-id></element-citation></ref><ref id="B94-nutrients-15-01559"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philippe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chakass</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thuru</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zerbib</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsicopoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geboes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bulois</surname><given-names>P.</given-names></name><name name-style="western"><surname>Breisse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vorng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Mu opioid receptor expression is increased in inflammatory bowel diseases: Implications for homeostatic intestinal inflammation</article-title><source>Gut</source><year>2006</year><volume>55</volume><fpage>815</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1136/gut.2005.080887</pub-id><pub-id pub-id-type="pmid">16299031</pub-id><pub-id pub-id-type="pmcid">PMC1856226</pub-id></element-citation></ref><ref id="B95-nutrients-15-01559"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bechara</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Kooy</surname><given-names>D.</given-names></name></person-group><article-title>Kappa receptors mediate the peripheral aversive effects of opiates</article-title><source>Pharmacol. Biochem. Behav.</source><year>1987</year><volume>28</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(87)90219-X</pub-id><pub-id pub-id-type="pmid">2825221</pub-id></element-citation></ref><ref id="B96-nutrients-15-01559"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chitnavis</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Baray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Northup</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Tuskey</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Behm</surname><given-names>B.W.</given-names></name></person-group><article-title>Opioid use and misuse in ulcerative colitis</article-title><source>World J. Gastrointest. Pharmacol. Ther.</source><year>2019</year><volume>10</volume><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.4292/wjgpt.v10.i1.22</pub-id><pub-id pub-id-type="pmid">30697446</pub-id><pub-id pub-id-type="pmcid">PMC6347648</pub-id></element-citation></ref><ref id="B97-nutrients-15-01559"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Targownik</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Nugent</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bugden</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>C.N.</given-names></name></person-group><article-title>The prevalence and predictors of opioid use in inflammatory bowel disease: A population-based analysis</article-title><source>Am. J. Gastroenterol.</source><year>2014</year><volume>109</volume><fpage>1613</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.230</pub-id><pub-id pub-id-type="pmid">25178702</pub-id></element-citation></ref><ref id="B98-nutrients-15-01559"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthes</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simonin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Valverde</surname><given-names>O.</given-names></name><name name-style="western"><surname>Slowe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kitchen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Befort</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dierich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le Meur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dolle</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene</article-title><source>Nature</source><year>1996</year><volume>383</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/383819a0</pub-id><pub-id pub-id-type="pmid">8893006</pub-id></element-citation></ref><ref id="B99-nutrients-15-01559"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hnasko</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Sotak</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Palmiter</surname><given-names>R.D.</given-names></name></person-group><article-title>Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin</article-title><source>J. Neurosci.</source><year>2007</year><volume>27</volume><fpage>12484</fpage><lpage>12488</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3133-07.2007</pub-id><pub-id pub-id-type="pmid">18003826</pub-id><pub-id pub-id-type="pmcid">PMC6673324</pub-id></element-citation></ref><ref id="B100-nutrients-15-01559"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerdjikov</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Beninger</surname><given-names>R.J.</given-names></name></person-group><article-title>Place preference induced by nucleus accumbens amphetamine is impaired by local blockade of Group II metabotropic glutamate receptors in rats</article-title><source>BMC Neurosci.</source><year>2006</year><volume>7</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2202-7-43</pub-id><pub-id pub-id-type="pmid">16734896</pub-id><pub-id pub-id-type="pmcid">PMC1501036</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="nutrients-15-01559-f001" orientation="portrait"><label>Figure 1</label><caption><p>Macrophage deletion of TNF&#945; and Ojeok-san administration does not impact disease progression in a chemical model of acute colitis. (<bold>A</bold>) Graphical depiction of the experimental design, (<bold>B</bold>) body weight, (<bold>C</bold>) water intake in control animals, (<bold>D</bold>) water intake in DSS-treated mice, (<bold>E</bold>) disease activity index in control animals, and (<bold>F</bold>) disease activity index in DSS-treated mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 10&#8211;18 mice per group. Three-way ANOVA for B. Letters indicate statistical significance (<italic toggle="yes">p</italic> &lt; 0.05) from <sup>a</sup> TNF&#945; fl/fl Control-Vehicle, <sup>b</sup> TNF&#945; fl/fl DSS-Vehicle, <sup>c</sup> TNF&#945; fl/fl LysMcre Control-Vehicle, <sup>d</sup> TNF&#945; fl/fl LysMcre DSS-Vehicle, <sup>e</sup> TNF&#945; fl/fl Control-OJS, <sup>f</sup> TNF&#945; fl/fl DSS-OJS, <sup>g</sup> TNF&#945; fl/fl LysMcre Control-OJS. Mixed-effects model followed by an uncorrected Fisher&#8217;s LSD post hoc test for C&#8211;F. * Indicates statistical difference from the TNF&#945; fl/fl DSS-Vehicle group on day 1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g001.jpg"/></fig><fig position="float" id="nutrients-15-01559-f002" orientation="portrait"><label>Figure 2</label><caption><p>Ojeok-san administration does not impact colon size and histopathology in a chemical model of acute colitis. (<bold>A</bold>) Representative H&amp;E staining of colonic tissue from control and (<bold>B</bold>) DSS-treated mice, (<bold>C</bold>) colon length, (<bold>D</bold>) colon weight, and (<bold>E</bold>) colonic histopathological score following acute DSS administration and OJS treatment in TNF&#945; fl/fl and TNF&#945; fl/fl-LysMCre mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 8&#8211;18 mice per group. Three-way ANOVA followed by uncorrected Fisher&#8217;s LSD post hoc test. Letters indicate statistical significance (<italic toggle="yes">p</italic> &lt; 0.05) from <sup>a</sup> TNF&#945; fl/fl Control-Vehicle, <sup>b</sup> TNF&#945; fl/fl DSS-Vehicle, <sup>c</sup> TNF&#945; fl/fl LysMcre Control-Vehicle, <sup>d</sup> TNF&#945; fl/fl LysMcre DSS-Vehicle, <sup>e</sup> TNF&#945; fl/fl Control-OJS, <sup>f</sup> TNF&#945; fl/fl DSS-OJS, <sup>g</sup> TNF&#945; fl/fl LysMcre Control-OJS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g002.jpg"/></fig><fig position="float" id="nutrients-15-01559-f003" orientation="portrait"><label>Figure 3</label><caption><p>Macrophage deletion of TNF&#945; influences villus length, and Ojeok-san administration influences goblet cell number and colonic IL6 expression. (<bold>A</bold>) Representative Alcian blue staining of colonic tissue from control and (<bold>B</bold>) DSS-treated mice; (<bold>C</bold>) Villus length, (<bold>D</bold>) goblet cell count, (<bold>E</bold>) IL-6 gene expression, and (<bold>F</bold>) NOD2 gene expression following acute DSS administration and OJS treatment in TNF&#945; fl/fl and TNF&#945; fl/fl-LysMCre mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 6&#8211;16 mice per group. Three-way ANOVA followed by an uncorrected Fisher&#8217;s LSD post hoc test. Letters indicate statistical significance (<italic toggle="yes">p</italic> &lt; 0.05) from <sup>a</sup> TNF&#945; fl/fl Control-Vehicle, <sup>b</sup> TNF&#945; fl/fl DSS-Vehicle, <sup>c</sup> TNF&#945; fl/fl LysMcre Control-Vehicle, <sup>d</sup> TNF&#945; fl/fl LysMcre DSS-Vehicle, <sup>e</sup> TNF&#945; fl/fl Control-OJS, <sup>f</sup> TNF&#945; fl/fl DSS-OJS, <sup>g</sup> TNF&#945; fl/fl LysMcre Control-OJS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g003.jpg"/></fig><fig position="float" id="nutrients-15-01559-f004" orientation="portrait"><label>Figure 4</label><caption><p>Macrophage deletion of TNF&#945; does not impact blood profile, but Ojeok-san administration diminishes lymphocyte levels in mice with colitis. (<bold>A</bold>) WBC, (<bold>B</bold>) RBC, (<bold>C</bold>) LYM, (<bold>D</bold>) HGB, (<bold>E</bold>) MON, (<bold>F</bold>) PLT, (<bold>G</bold>) NEU following acute DSS administration and OJS treatment in TNF&#945; fl/fl and TNF&#945; fl/fl-LysMCre mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 7&#8211;18 mice per group. Three-way ANOVA followed by uncorrected Fisher&#8217;s LSD post hoc test. Letters indicate statistical significance (<italic toggle="yes">p</italic> &lt; 0.05) from <sup>a</sup> TNF&#945; fl/fl Control-Vehicle, <sup>b</sup> TNF&#945; fl/fl DSS-Vehicle, <sup>c</sup> TNF&#945; fl/fl LysMcre Control-Vehicle, <sup>d</sup> TNF&#945; fl/fl LysMcre DSS-Vehicle, <sup>e</sup> TNF&#945; fl/fl Control-OJS, <sup>f</sup> TNF&#945; fl/fl DSS-OJS, <sup>g</sup> TNF&#945; fl/fl LysMcre Control-OJS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g004.jpg"/></fig><fig position="float" id="nutrients-15-01559-f005" orientation="portrait"><label>Figure 5</label><caption><p>Macrophage deletion of TNF&#945; does not impact mechanical sensitivity, but Ojeok-san administration improves mechanical hyperalgesia in mice with colitis. (<bold>A</bold>) Mechanical threshold to stimuli with von Frey filaments; gene expression of (<bold>B</bold>) calcr, (<bold>C</bold>) oprm, and (<bold>D</bold>) oprk following acute DSS administration and OJS treatment in TNF&#945; fl/fl and TNF&#945; fl/fl-LysMCre mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 4&#8211;18 mice per group. Three-way ANOVA followed by uncorrected Fisher&#8217;s LSD post hoc test. Letters indicate statistical significance (<italic toggle="yes">p</italic> &lt; 0.05) from <sup>a</sup> TNF&#945; fl/fl Control-Vehicle, <sup>b</sup> TNF&#945; fl/fl DSS-Vehicle, <sup>c</sup> TNF&#945; fl/fl LysMcre Control-Vehicle, <sup>d</sup> TNF&#945; fl/fl LysMcre DSS-Vehicle, <sup>e</sup> TNF&#945; fl/fl Control-OJS, <sup>f</sup> TNF&#945; fl/fl DSS-OJS, <sup>g</sup> TNF&#945; fl/fl LysMcre Control-OJS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g005.jpg"/></fig><fig position="float" id="nutrients-15-01559-f006" orientation="portrait"><label>Figure 6</label><caption><p>Four-week administration of OJS does not impact disease progression or show rewarding properties in the mdr1a KO mouse model of spontaneous colitis. (<bold>A</bold>) Graphical depiction of spatial conditioning place-preference protocol; (<bold>B</bold>) body weight, (<bold>C</bold>) colon length, (<bold>D</bold>) colon weight, (<bold>E</bold>) percent time spend on the OJS-paired side compartment during the test sessions, (<bold>F</bold>) WBC, (<bold>G</bold>) LYM, (<bold>H</bold>) MON, (<bold>I</bold>) NEU, (<bold>J</bold>) RBC, (<bold>K</bold>) HGB, and (<bold>L</bold>) PLT in vehicle- and OJS-treated mrd1a KO mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 3 mice per group. Two-way RM AVOVA was conducted for (<bold>A</bold>,<bold>E</bold>). Two-tail unpaired <italic toggle="yes">t</italic>-test was conducted for (<bold>C</bold>,<bold>D</bold>), and (<bold>F</bold>&#8211;<bold>L</bold>). * Indicates statistical significance between groups, <italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g006.jpg"/></fig><fig position="float" id="nutrients-15-01559-f007" orientation="portrait"><label>Figure 7</label><caption><p>Five-week administration of OJS does not impact disease progression, but improves mechanical hyperalgesia, without promoting reward-seeking behavior in the IL-10 KO mouse model of spontaneous colitis. (<bold>A</bold>) A graphical depiction of spatial conditioning place-preference protocol, (<bold>B</bold>) body weight, (<bold>C</bold>) colon length, (<bold>D</bold>) colon weight, (<bold>E</bold>) mechanical threshold to stimuli with von Frey filaments, (<bold>F</bold>) percentage of time spent on the OJS-paired side compartment during the test sessions, (<bold>G</bold>) WBC, (<bold>H</bold>) LYM, (<bold>I</bold>) MON, (<bold>J</bold>) NEU, (<bold>K</bold>) RBC, (<bold>L</bold>) HGB, and (<bold>M</bold>) PLT in vehicle- and OJS-treated IL-10 KO mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 8&#8211;9 mice per group. Two-way RM AVOVA was conducted for F. Two-tail unpaired <italic toggle="yes">t</italic>-test was conducted for (<bold>B</bold>&#8211;<bold>E</bold>), and (<bold>G</bold>&#8211;<bold>M</bold>). * Indicates statistical significance between groups, <italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g007.jpg"/></fig><fig position="float" id="nutrients-15-01559-f008" orientation="portrait"><label>Figure 8</label><caption><p>A single dose of OJS does not impact locomotor activity or sleep behavior in an IL-10 KO mouse model of spontaneous colitis. (<bold>A</bold>) Distance that IL-10 KO vehicle- and OJS-treated mice travelled in their home cage during the light and night cycle, (<bold>B</bold>) Time that the IL-10 KO vehicle- and OJS-treated mice spent sleeping during the light and night cycle. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 8 mice per group. Two-way RM AVOVA. ^ <italic toggle="yes">p</italic> &lt; 0.05 Indicates statistical significance between night and light cycle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g008.jpg"/></fig><fig position="float" id="nutrients-15-01559-f009" orientation="portrait"><label>Figure 9</label><caption><p>OJS reduces aversive behavior produced by colorectal balloon distension in C57BL6 mice. (<bold>A</bold>) Graphical depiction of spatial conditioning place-aversion protocol, (<bold>B</bold>) percentage of time spend in the preferred (non-OJS-paired side) compartment during the test sessions, (<bold>C</bold>) body weight, (<bold>D</bold>) WBC, (<bold>E</bold>) LYM, (<bold>F</bold>) MON, (<bold>G</bold>) NEU, (<bold>H</bold>) RBC, (<bold>I</bold>) HGB, and (<bold>J</bold>) PLT in vehicle- and OJS-treated C57BL6 mice. Values are represented as mean &#177; SEM; <italic toggle="yes">n</italic> = 7&#8211;10 mice per group. Two-way RM AVOVA for B. <sup>$</sup> Indicates statistical significance from baseline in C57BL6 Vehicle mice. <sup>#</sup> Indicates statistical significance from baseline in C57BL6 OJS-treated mice. Two-tail unpaired <italic toggle="yes">t</italic>-test for (<bold>C</bold>&#8211;<bold>J</bold>), * <italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-15-01559-g009.jpg"/></fig></floats-group></article></pmc-articleset>